<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Use and impact of antiretroviral therapy for HIV infection in resource-limited settings</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Use and impact of antiretroviral therapy for HIV infection in resource-limited settings</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Use and impact of antiretroviral therapy for HIV infection in resource-limited settings</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily P Hyle, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Scott Dryden-Peterson, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 28, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H12409041"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The Joint United Nations Programme on HIV and AIDS (UNAIDS) integrates the efforts of various United Nation organizations, including the World Health Organization (WHO), to control the global HIV epidemic, with the goal of eliminating HIV/AIDS as a public health threat by 2030 [<a href="#rid1">1</a>]. Expansive scale-up of services as part of UNAIDS initiatives since the beginning of the century has resulted in tremendous increases in antiretroviral access and coverage in resource-limited settings as well as associated reductions in new HIV cases, AIDS-related deaths, and overall mortality [<a href="#rid2">2,3</a>]. Despite these achievements, too many people with HIV worldwide are not receiving ART.</p><p>The impact of ART on HIV infection in resource-limited settings will be discussed here. The overall benefits of ART and information on the global epidemic are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection"</a>.)</p><p class="headingAnchor" id="H12409048"><span class="h1">EPIDEMIOLOGY OF HIV</span><span class="headingEndMark"> — </span>Of the estimated 38 million individuals with HIV worldwide in 2019, 25.6 million are in sub-Saharan Africa, where the overall prevalence is approximately 5 percent [<a href="#rid4">4,5</a>]. In some African countries, the prevalence exceeds 20 percent. More than half of the population with HIV in sub-Saharan Africa is women and children. HIV prevalence in Southeast Asia is substantially lower (0.6 percent), representing approximately four million people with HIV living in this under-resourced region. In Latin America and the Caribbean, infection rates vary by region, with estimated prevalences ranging from 0.5 to 2 percent. Markedly high rates of infection exist within certain risk groups, such as men who have sex with men, prisoners, commercial sex workers, and people who use injection drugs. The global epidemiology of HIV is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection", section on 'Worldwide statistics'</a>.)</p><p class="headingAnchor" id="H1275953246"><span class="h1">RECOMMENDATIONS FROM THE WORLD HEALTH ORGANIZATION</span></p><p class="headingAnchor" id="H1275953781"><span class="h2">Initiation of ART</span><span class="headingEndMark"> — </span>In 2015, the World Health Organization (WHO) revised longstanding guidance to withhold treatment until development of immunodeficiency and instead recommended initiation of antiretroviral therapy (ART) for all people with HIV, regardless of CD4 cell count or clinical stage [<a href="#rid6">6</a>]. Those with advanced HIV disease (clinical stage 3 or 4 disease (<a class="graphic graphic_table graphicRef55105" href="/z/d/graphic/55105.html" rel="external">table 1</a>)) or a CD4 cell count of &lt;200 cells/microL are a priority for ART initiation. In general, initiation of ART should be offered within seven days of an HIV diagnosis or, for those who are ready to start therapy, on the day of diagnosis [<a href="#rid7">7</a>]. For people who have suspected or documented coinfection with tuberculosis (TB) or cryptococcal meningitis, ART initiation is deferred until those infections have been ruled out or treatment for those infections has been initiated. (See  <a class="medical medical_review" href="/z/d/html/85376.html" rel="external">"Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a>.)</p><p>The rationale for recommending ART initiation for all, even for those with high CD4 cell counts, includes: </p><p class="bulletIndent1"><span class="glyph">●</span>Benefit of ART at any CD4 cell count with regards to both AIDS- and non-AIDS-associated morbidity and mortality (see <a class="local">'Effect of ART on mortality'</a> below and <a class="local">'Effect of ART on other comorbidities'</a> below)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Substantial reduction of sexual transmission of HIV to uninfected partners with the use of ART (see <a class="local">'Impact of ART on transmission'</a> below) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Increasing availability of agents that are convenient, less toxic, and less costly </p><p></p><p>Similar reasons have been used to promote ART for all people with HIV in resource-rich settings. Mounting evidence has suggested that initiation of ART early during infection (even at CD4 cell counts higher than 500 cells/microL, which was the previously recommended threshold for initiation) is also beneficial in resource-limited settings. (See <a class="local">'Optimal timing of ART'</a> below.)</p><p>Of note, these recommendations apply only to individuals infected with HIV-1. The use of ART in people with HIV-2 infection is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p class="headingAnchor" id="H3091491123"><span class="h2">Regimen selection</span><span class="headingEndMark"> — </span>WHO guidelines specify a first-line regimen of <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> in combination with a nucleoside reverse transcriptase inhibitor (NRTI) backbone for all populations with HIV, including females of childbearing potential and pregnant females [<a href="#rid8">8</a>]. <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">Efavirenz</a> at low dose (400 mg) in combination with a NRTI backbone is recommended as an alternative first-line regimen. In locations where the prevalence of resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) such as efavirenz is ≥10 percent, NNRTI-based regimens as first-line ART should be avoided. </p><p>WHO guidance highlights several benefits of <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a>, including expected lower drug-drug interactions, decreased risk of development of drug resistance, and improved efficacy compared with <a class="drug drug_general" data-topicid="8731" href="/z/d/drug information/8731.html" rel="external">efavirenz</a>. As an example, in a randomized trial of over 1000 people with HIV in South Africa, there was a nonsignificant trend towards higher rates of viral suppression (&lt;50 copies/mL) with two dolutegravir-based regimens compared with an efavirenz-based regimen (84 and 85 versus 79 percent) [<a href="#rid9">9</a>]. Similar findings were reported from a trial of over 600 people with HIV in Cameroon comparing a dolutegravir-based regimen to a regimen containing a lower dose of efavirenz (400 mg) [<a href="#rid10">10</a>].</p><p>The WHO also recommends <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> in combination with an NRTI backbone during pregnancy and breastfeeding. Long-term nationwide surveillance in Botswana has observed comparable risk of neural tube defects with exposure to dolutegravir (0.11 percent, 95% CI 0.06-0.19) and other ART regimens (0.11 percent, 95% CI 0.07-0.16) [<a href="#rid11">11</a>], allying earlier concerns of increased risk [<a href="#rid12">12</a>]. Rates of stillbirth or prematurity are also similar [<a href="#rid13">13</a>] and viral suppression may be higher [<a href="#rid14">14</a>] for females receiving dolutegravir-containing ART.</p><p class="headingAnchor" id="H5747663"><span class="h2">Monitoring for and management of treatment failure</span><span class="headingEndMark"> — </span>For most patients, treatment failure is defined as a persistent HIV viral load &gt;1000 copies/mL for three months or more after at least six months of ART [<a href="#rid6">6,15</a>]. However, if a patient is on an NNRTI-based regimen, treatment failure is defined as a one-time HIV viral load &gt;1000 copies/mL, given the known lower resistance threshold. Patients with treatment failure should be switched to an appropriate regimen. </p><p>If HIV RNA testing is not easily available, treatment failure should be indirectly assessed through CD4 cell count and clinical monitoring, with targeted viral load testing used as a confirmatory test when available. (See <a class="local">'ART efficacy'</a> below.) </p><p>Second-line regimens following treatment failure are typically chosen without knowledge of the presence of resistance mutations. </p><p class="bulletIndent1"><span class="glyph">●</span>In patients failing a dolutegravir-based regimen, the WHO recommends a boosted protease inhibitor plus at least two NRTIs as a second-line regimen. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients failing a NNRTI-based regimen, the WHO recommends <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> (or a boosted protease inhibitor if dolutegravir is contraindicated or unavailable) plus at least two NRTIs as a second-line regimen. </p><p></p><p>NRTIs used in the second-line regimen should be informed by the NRTIs used in the failing first-line regimen. As an example, if tenofovir and <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> were the NRTIs used in the first-line regimen, the second-line NRTIs should be <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a> and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>. Despite concerns that failure on an NRTI-containing regimen would lead to cross-resistance to and thus decreased efficacy with other NRTI agents, NRTI-containing second-line regimens appear to maintain efficacy [<a href="#rid16">16-20</a>]. </p><p>In an open-label randomized trial of 464 patients in sub-Saharan Africa with HIV who failed an NNRTI-based regimen with tenofovir and <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a>, a switch to <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> versus a protease inhibitor resulted in similar rates of HIV viral load suppression (&lt;400 copies/mL) at 48 and 96 weeks, approximately 90 percent in each group [<a href="#rid20">20,21</a>]. As a second randomization, patients were assigned to either remain on tenofovir or switch to <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>, and both of these groups also experienced similar rates of viral load suppression (92 versus 90 percent). However, since NRTI mutations are common among patients failing NNRTI-based regimens, longer term follow-up is needed before recommending continuing the NRTI backbone of the failing regimen. </p><p>In resource-rich settings, genotypic testing is used to guide second-line therapy. However, genotypic testing is not readily accessible in many resource-limited settings and the WHO does not recommend routine genotype testing in patients failing first-line ART regimens. Although an unblinded, randomized trial of 840 patients in sub-Saharan Africa demonstrated that genotypic testing did not improve rates of viral load suppression at nine months in patients failing first-line NNRTI-based regimens, poor adherence and high number of patients switching to second-line therapy in both groups may have reduced the ability to detect a difference in outcome [<a href="#rid22">22</a>]. </p><p class="headingAnchor" id="H1561054848"><span class="h2">Prevention of coinfections</span><span class="headingEndMark"> — </span>WHO guidelines recommend the following evaluation and preventive interventions at the time of HIV diagnosis and ART initiation (<a class="graphic graphic_algorithm graphicRef117438" href="/z/d/graphic/117438.html" rel="external">algorithm 1</a>) [<a href="#rid7">7,15</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>For all people with HIV – Screen for clinical symptoms of active tuberculosis and test for latent tuberculosis infection, if such tests are available. Treat for latent tuberculosis with <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> in those who have unknown or positive tuberculin skin tests and are unlikely to have active tuberculosis. The duration depends on the regional prevalence of tuberculosis. Details on the evaluation and treatment of latent tuberculosis in people with HIV are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/115049.html" rel="external">"Tuberculosis infection (latent tuberculosis) in adults: Approach to diagnosis (screening)"</a> and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additionally, for people with HIV five years and older who have CD4 counts &lt;350 cells/microL or WHO clinical stage 3 or 4 disease (<a class="graphic graphic_table graphicRef55105" href="/z/d/graphic/55105.html" rel="external">table 1</a>), for children with HIV younger than five years, and for people with HIV who live in a region where malaria and/or bacterial infections are common (regardless of CD4 cell count) – Administer <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis.</p><p></p><p class="bulletIndent1">WHO recommends continuing <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis until the person is clinically stable on ART, with evidence of immune recovery and virologic suppression. However, indefinite prophylaxis regardless of HIV clinical status is recommended in regions where malaria and bacterial infection are common.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additionally, for adults and adolescents with HIV and CD4 cell count ≤100 cells/microL – Screen with a cryptococcal antigen test prior to ART initiation. For those with a positive test (or those without access to cryptococcal antigen testing) but without evidence of cryptococcal meningitis, preemptively treat with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>. This approach can also be considered for people with CD4 counts between 100 and 200 cells/microL [<a href="#rid23">23</a>]. Antifungal therapy can be discontinued once the person is clinically stable on ART, has received antifungal therapy for at least one year, and has a sustained CD4 cell count ≥200 cells/microL or a sustained CD4 cell count ≥100 cells/microL with a suppressed viral load. Details on the evaluation for and prevention of cryptococcal infection in people with HIV are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.)</p><p></p><p>These recommendations are based on data demonstrating reduced morbidity and mortality with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis and with preemptive therapy of cryptococcal and latent tuberculosis infection. (See <a class="local">'Impact of prophylaxis against coinfections'</a> below.)</p><p class="headingAnchor" id="H12409062"><span class="h1">EFFECT OF ART ON MORTALITY</span></p><p class="headingAnchor" id="H9845923"><span class="h2">Treatment-naïve patients</span><span class="headingEndMark"> — </span>Meta-analyses of antiretroviral therapy (ART) trials in resource-limited settings, along with subsequent larger cohort studies and a randomized trial, have demonstrated that treatment-induced viral suppression and immune recovery lead to improved clinical status and reduced mortality [<a href="#rid24">24-28</a>]. Reductions in mortality are evident even among people with advanced immunosuppression [<a href="#rid26">26,29-31</a>], and the magnitude of mortality reduction has been generally similar to that in resource-rich countries. One prospective cohort study in Uganda found that the life expectancy of 22,315 people with HIV receiving ART was comparable with the national average, despite the use of less potent and more toxic treatment regimens than those in use in resource-rich settings [<a href="#rid26">26</a>]. </p><p>However, disproportionately high mortality has been observed among some people soon after ART initiation, especially among profoundly immunosuppressed persons [<a href="#rid24">24,27,30,32-35</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Of more than 21,000 people who were enrolled into HIV care in Zambia, 71 percent of the total number of deaths (n = 1142) occurred within 90 days of starting ART, while the remaining 29 percent occurred after 90 days [<a href="#rid33">33</a>]. In a multivariable analysis, mortality was strongly associated with a low baseline CD4 cell count (range 50 to 199 cells/microL; adjusted hazard ratio [HR] 2.2; 95% CI 1.5-3.1).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis of adults initiating ART in sub-Saharan Africa demonstrated that the highest mortality rates occurred among those adults with advanced AIDS; specifically, having a baseline CD4 count &lt;50 cells/microL and World Health Organization (WHO) stage 4 disease was associated with twice the likelihood of death (summary HR, 2.2; 95% CI 1.5-3.2) (<a class="graphic graphic_table graphicRef55105" href="/z/d/graphic/55105.html" rel="external">table 1</a>) [<a href="#rid34">34</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In a separate meta-analysis of adults initiating ART in low- and middle-income countries, mortality rates ranged from 7 to 17 percent at one year after ART initiation. There was an increased risk of death with male gender, age greater than 40 years, low BMI, anemia, advanced clinical HIV disease, and low CD4 counts at initiation [<a href="#rid36">36</a>].</p><p></p><p>Poor ART responses are also related to advanced age [<a href="#rid37">37</a>], bone marrow suppression, low body weight, and malnutrition [<a href="#rid33">33,38</a>]. </p><p>Because the highest mortality rates occur among those with severe immunosuppression, greater survival benefit may be attained with expanded availability of ART prior to the onset of advanced disease [<a href="#rid26">26,39</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a cohort study of over 22,000 Ugandan adults enrolled in ART clinics, there was an association with lower mortality in people who initiated ART at higher CD4 counts after adjustment for sex, WHO disease stage, and year of ART initiation [<a href="#rid27">27</a>]. The relative risk of death was 0.75 (95% CI 0.65–0.88) in those with baseline CD4 counts between 50 and 99 cells/microL and 0.41 (95% CI 0.33–0.51) in those with baseline CD4 counts ≥250 cells/microL compared with adults who initiated ART at CD4 counts &lt;50 cells/microL.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other observational data have also supported earlier initiation of ART in people with CD4 counts &gt;200 cells/microL, not only in reducing mortality, but also in improving overall rates of treatment-induced viral suppression compared with deferred ART [<a href="#rid40">40</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Initiation of ART in people with CD4 counts ≤350 cells/microL<sup> </sup>has mortality benefit for all patients with HIV. In a randomized trial conducted in Haiti, 816 study participants with a baseline CD4 count between 200 and 350 cells/microL were randomly assigned to either "standard ART" or "early ART" [<a href="#rid28">28</a>]. "Standard ART" was initiated at the onset of clinical AIDS or a CD4 cell count &lt;200 cells/microL, whereas "early ART" was initiated within two weeks of study enrollment. A significantly higher number of deaths occurred in the standard rather than in the early ART arm (ie, 23 versus 6 deaths; HR 4, 95% CI 1.6-9.8). </p><p></p><p>The mortality benefits of ART likely extend to individuals with CD4 cell counts &gt;350 cells/microL through reduction in severe illnesses<sup> </sup>[<a href="#rid41">41-43</a>]. WHO guidelines for initiation of ART in resource-limited settings are discussed elsewhere. (See <a class="local">'Recommendations from the World Health Organization'</a> above.)</p><p class="headingAnchor" id="H3410357"><span class="h2">Long-term follow-up</span><span class="headingEndMark"> — </span>Benefits of ART in resource-limited settings are retained during follow-up. In a multi-site longitudinal cohort with 29,175 people who initiated care, 19,967 people with HIV were followed for more than six months and 820 people were followed for more than four years (median follow-up time 1.6 years) [<a href="#rid42">42</a>]. Overall, mortality and loss to follow-up were low (3 percent and 9 percent, respectively). Immune reconstitution was substantial among those with advanced immunosuppression (395 cells/microL at five years from a median nadir of 114 cells/microL); the trajectory of CD4 cell gain on ART was greater among those who initiated treatment at higher CD4 counts. </p><p>In a separate study of people initiating ART at multiple South African clinical sites, mortality rates at two to four years post-ART initiation were 12-fold lower than mortality rates at three months after ART initiation [<a href="#rid44">44</a>]. An estimation of life-expectancy of people with HIV on ART in Uganda suggested that people engaged in care and on ART could live over 20 additional years, which is near normal for adults in the region; those who initiated ART at higher CD4 counts had longer life expectancy [<a href="#rid26">26</a>]. In a population cohort study of more than 101,000 individuals in rural KwaZulu-Natal, South Africa, after eight years of ART availability to the public (from 2003 to 2011), the average adult life expectancy increased by 11.3 years (49.2 years to 60.5 years) [<a href="#rid45">45</a>].</p><p class="headingAnchor" id="H23835331"><span class="h2">Gender differences in mortality</span><span class="headingEndMark"> — </span>In resource-limited settings, men with HIV appear to have a higher risk of death than women despite ART [<a href="#rid46">46-48</a>]. In a retrospective study of 46,201 individuals with HIV in South Africa initiating ART between 2002 and 2009, the mortality rate was higher among men than women (8.5 versus 5.7 deaths per 100 person-years) [<a href="#rid46">46</a>]. Although men were older, had lower median CD4 cell counts, and were more likely to have advanced HIV (WHO stage III to IV) at ART initiation compared with women, a difference in mortality rate remained significant (adjusted HR 1.31, 95% CI 1.22-1.41) after adjusting for these and other variables. Men also had a higher rate of loss to follow-up than women, but even among those patients who achieved viral suppression to &lt;400 copies/mL on ART, the risk of death remained higher for men. A proportion of the excess mortality was thought to reflect the HIV-unrelated mortality differences observed between men and women in resource-limited settings. </p><p class="headingAnchor" id="H9845930"><span class="h2">Second-line therapy</span><span class="headingEndMark"> — </span>Second-line therapy is increasingly available for people with HIV in resource-limited communities who experience therapy-limiting toxicities or clinical failure, especially when due to the emergence of resistance to non-nucleoside reverse transcriptase inhibitor and NRTI agents. Outcomes data remain mixed regarding those who change to second-line regimens. A large observational multi-center cohort in Asia and Africa demonstrated high failure rates in addition to substantial morbidity and mortality after change to second-line therapy [<a href="#rid49">49</a>], but other cohort studies have reported virologic suppression rates of &gt;70 percent on second-line regimens and demonstrated a beneficial effect of second-line therapy on mortality and immune reconstitution [<a href="#rid50">50-53</a>].</p><p>Failure of second-line regimens has been associated with ongoing poor adherence [<a href="#rid52">52</a>], and emergence of PI mutations remains rare [<a href="#rid53">53,54</a>]. (See <a class="local">'Drug resistance'</a> below.)</p><p class="headingAnchor" id="H12409069"><span class="h1">EFFECT OF ART ON OTHER COMORBIDITIES</span><span class="headingEndMark"> — </span>A growing body of evidence demonstrates the benefit of antiretroviral therapy (ART) in specifically attenuating the effects of HIV on a variety of highly prevalent illnesses in developing countries, as discussed below.</p><p class="headingAnchor" id="H12409076"><span class="h2">Tuberculosis</span><span class="headingEndMark"> — </span>Substantial additional morbidity and mortality from tuberculosis (TB) coinfection occurs in untreated people with HIV in resource-limited settings with evidence of a fivefold increased risk of active TB in patients with HIV [<a href="#rid55">55</a>]. This risk of TB increases with declining immunity. (See  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.)</p><p>People with HIV may have active pulmonary TB without clinical symptoms [<a href="#rid55">55-57</a>]. Furthermore, unsuspected TB is associated with higher rates of morbidity and mortality after initiation of ART compared with those without concomitant TB [<a href="#rid58">58</a>]. Given the high prevalence of coinfection in many resource-limited regions, intensified TB case finding with screening, regardless of symptoms, may help in case identification and in reducing early morbidity when initiating ART [<a href="#rid56">56,59</a>].</p><p class="headingAnchor" id="H8959030"><span class="h3">TB incidence</span><span class="headingEndMark"> — </span>Widespread use of ART has been associated with a decreased incidence of tuberculosis (TB) and up to a 70 percent reduction in death among people with HIV coinfected with tuberculosis [<a href="#rid28">28,60-63</a>]. </p><p class="bulletIndent1"><span class="glyph">●</span>In a treatment trial conducted in Haiti, 816 people with HIV were randomly assigned to early ART (two weeks after enrollment) or to standard ART (initiation of ART when CD4 counts declined to ≤200 cells/microL or for the onset of clinical AIDS) with <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> prophylaxis administered to all study participants. Early initiation of ART was associated with a twofold decline in TB incidence over a median follow-up of 21 months [<a href="#rid28">28</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Even among people with higher CD4 cell counts, ART reduces the incidence of TB. In a randomized trial from Ivory Coast of over 2000 people with HIV and CD4 cell counts &lt;800 cells/microL, there was a lower rate of active tuberculosis among individuals who initiated ART at the time of enrollment compared with those who initiated ART once the World Health Organization (WHO) criteria were met, which evolved over the course of the trial (hazard ratio 0.5, 95% CI 0.32-0.74) [<a href="#rid41">41</a>]. Participants in each group were also randomly assigned to receive six months of <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> or not, and this intervention also reduced the incidence of TB. (See <a class="local">'Optimal timing of ART'</a> below and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection"</a>.)</p><p></p><p class="headingAnchor" id="H98350889"><span class="h3">TB treatment</span><span class="headingEndMark"> — </span>Coinfection with tuberculosis (TB) and HIV poses challenging clinical management issues. There are multiple pharmacologic interactions between ART and anti-tuberculosis medications with additive toxicities [<a href="#rid64">64</a>]. Additionally, immune recovery secondary to ART can lead to paradoxical worsening of clinical symptoms in people with tuberculosis; this clinical scenario is referred to as the immune reconstitution inflammatory syndrome (IRIS). (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy"</a> and  <a class="medical medical_review" href="/z/d/html/111683.html" rel="external">"Diagnosis of pulmonary tuberculosis in adults"</a>.) </p><p>However, data from several trials demonstrate that the mortality reduction observed with early ART (within 2 to 12 weeks after initiating anti-tuberculous therapy) outweighs the potential morbidity of IRIS [<a href="#rid65">65-68</a>]. People with TB meningitis may be an exception to this observation. In one trial of 253 people with HIV and TB meningitis, there was no difference in mortality but an increase in serious adverse events among patients randomly assigned to immediate (within seven days of TB treatment initiation) compared with deferred (after two months) ART initiation [<a href="#rid69">69</a>]. These data and the timing of ART initiation in the setting of TB are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8013.html" rel="external">"Treatment of drug-susceptible pulmonary tuberculosis in nonpregnant adults with HIV infection: Initiation of therapy", section on 'Antiretroviral therapy'</a>.)</p><p class="headingAnchor" id="H12409083"><span class="h2">Malaria</span><span class="headingEndMark"> — </span>Since the beginning of the HIV pandemic, malarial infections have doubled in parts of sub-Saharan Africa [<a href="#rid70">70,71</a>] with a higher incidence among those people with low CD4 counts [<a href="#rid72">72</a>]. In one observational cohort of 1371 people with HIV in Uganda, incidence rates of symptomatic malaria infection were higher among people with lower CD4 cell counts (eg, 140, 93, and 57 cases per 1000 person-years of follow-up for CD4 T cell counts &lt;200, 200 to 499, and &gt;500 cells/microL, respectively) [<a href="#rid72">72</a>]. ART initiation in Uganda has been shown to reduce malaria incidence by 64 percent [<a href="#rid73">73</a>]. (See  <a class="medical medical_review" href="/z/d/html/5709.html" rel="external">"Malaria: Clinical manifestations and diagnosis in nonpregnant adults and children"</a>.)</p><p class="headingAnchor" id="H12409090"><span class="h2">Cryptococcus</span><span class="headingEndMark"> — </span>The historically high mortality rates associated with cryptococcal infections in sub-Saharan Africa have also declined with the availability of ART. In a retrospective study of 127 people with cryptococcal meningitis conducted from 1997 to 2005, those who initiated ART were 37 times more likely to survive cryptococcal infection than those who did not [<a href="#rid74">74</a>]. Cohorts in Cape Town and Botswana have demonstrated that ART use was associated with significantly reduced inpatient mortality from cryptococcal meningitis (8 percent versus 21 percent [<a href="#rid75">75</a>]) and reduced mortality at one year (41 percent versus 76 percent [<a href="#rid76">76</a>]) compared with people not yet on therapy at the time of admission. </p><p>A paradoxical clinical worsening of symptoms in people with cryptococcal meningitis can occur in the setting of ART initiation and immune recovery, similar to that in mycobacterial disease. Immune reconstitution with cryptococcal disease can be associated with increased intracranial pressure and significant morbidity and mortality if not appropriately monitored [<a href="#rid77">77,78</a>]. The optimal timing of ART initiation for people with cryptococcal meningitis is discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/85376.html" rel="external">"Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV"</a>.)</p><p>The diagnosis and management of cryptococcal infection are also discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H12409097"><span class="h2">Viral hepatitis</span><span class="headingEndMark"> — </span>Rates of infection with either hepatitis B or C viruses are high in Africa and Asia. ART use in people with HIV and viral hepatitis raises two main concerns: (a) the effects of viral hepatitis infections on immune recovery; and (b) the risk of drug-associated hepatotoxicity. (See  <a class="medical medical_review" href="/z/d/html/3640.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of hepatitis B in patients living with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3652.html" rel="external">"Treatment of chronic hepatitis B in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/3701.html" rel="external">"Treatment of chronic hepatitis C virus infection in the patient with HIV"</a>.)</p><p>Despite concerns regarding the potential for negative immunomodulatory effects of viral hepatitis on ART-associated immune reconstitution, data from resource-limited settings have not demonstrated worse outcomes for ART initiation in HBV/HIV-coinfected people. In studies from Thailand, Nigeria, South Africa, and Malawi, people with HBV/HIV coinfection had delayed CD4 gains in early response to ART but attained equivalent immunologic recovery and virologic suppression at 48 to 72 weeks [<a href="#rid79">79-82</a>]. </p><p>Given the data on hepatotoxicity from resource-rich settings, there is ongoing concern regarding the risk of drug-induced liver injury in HIV/hepatitis-coinfected adults in resource-limited countries [<a href="#rid83">83</a>]. In studies of HIV/HBV-coinfected people on ART from resource-limited settings, hepatotoxicity has been reported more frequently in people with higher HBV DNA viral loads but has not been treatment limiting [<a href="#rid79">79,81,82</a>].</p><p class="headingAnchor" id="H12409104"><span class="h2">Leishmaniasis</span><span class="headingEndMark"> — </span>The incidence of leishmania/HIV coinfection is increasing worldwide. Regions that are considered endemic are expanding through India, Eastern Africa, the Middle East, the Mediterranean basin, and South America. </p><p>Similar to the negative clinical impact of TB and malaria infection on HIV infection, coinfection with visceral leishmaniasis contributes to accelerated HIV disease progression and increased mortality [<a href="#rid84">84,85</a>]. (See  <a class="medical medical_review" href="/z/d/html/5732.html" rel="external">"Visceral leishmaniasis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/5710.html" rel="external">"Visceral leishmaniasis: Treatment"</a>.)</p><p>In a three-year prospective study of 356 people with HIV and leishmaniasis, ART use was associated with decreased risk of relapse, although there was no effect on mortality [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H15082906"><span class="h2">Cancer</span><span class="headingEndMark"> — </span>Since the initial descriptions of AIDS in Africa [<a href="#rid86">86,87</a>], malignancies have been a major cause of morbidity and mortality in individuals with HIV in resource-limited settings. The majority of cancers in the context of HIV infection are linked to oncogenic viral infections, particularly human papilloma virus (HPV), Epstein-Barr virus, and Kaposi sarcoma herpesvirus [<a href="#rid88">88</a>]. The risk is elevated two- to fivefold compared with individuals without HIV [<a href="#rid89">89</a>]. Expansion of ART for individuals with low CD4 cell counts in sub-Saharan Africa has been associated with reduced individual cancer risk for Kaposi sarcoma, the most common cancer in individuals with HIV in the region, but increased population incidence of cervical and other HPV-associated cancers as well as non-Hodgkin lymphoma [<a href="#rid90">90,91</a>]. Initiation of ART prior to the development of immunosuppression, as currently recommended by the WHO, may reduce risk of cancer further [<a href="#rid41">41-43</a>]. The epidemiology and management of HIV-associated cancers are discussed in greater detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8035.html" rel="external">"HIV infection and malignancy: Epidemiology and pathogenesis"</a> and  <a class="medical medical_review" href="/z/d/html/8036.html" rel="external">"HIV infection and malignancy: Management considerations"</a>.)</p><p class="headingAnchor" id="H630998111"><span class="h1">OPTIMAL TIMING OF ART</span><span class="headingEndMark"> — </span>Initiation of antiretroviral therapy (ART) early in the course of HIV infection rather than waiting for CD4 cell decline reduces severe AIDS and non-AIDS illnesses. Several trials in resource-limited settings have demonstrated the benefit of ART at progressively higher CD4 cell counts.</p><p class="bulletIndent1"><span class="glyph">●</span>A trial in Haiti of over 800 people reported morbidity and mortality benefits of ART initiation at CD4 cell counts of 200 to 350 compared with &lt;200 cells/microL [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In an international trial of over 1700 people, HIV-related clinical events were reduced with ART initiation at CD4 cell counts between 250 and 500 compared with ≤250 cells/microL [<a href="#rid92">92</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The benefit of even earlier ART initiation was demonstrated in the multicenter TEMPRANO trial in Ivory Coast that included 2056 individuals with HIV who had CD4 cell counts &lt;800 but did not meet the World Health Organization (WHO) criteria for ART initiation (which evolved over the course of the trial, ranging from a CD4 cell threshold of 200 to 500 cells/microL) [<a href="#rid41">41</a>]. Participants were randomly assigned to receive early ART at the time of enrollment or deferred ART, which was initiated once the person met WHO criteria. After 30 months of follow-up, the probability of the composite primary end point of death from any cause, AIDS-defining disease, non–AIDS-defining cancer, or non–AIDS-defining invasive bacterial disease was 6.6 percent with early ART versus 11.4 percent with deferred ART (hazard ratio [HR] 0.56, 95% CI 0.41-0.76). A similar effect was observed among those with a baseline CD4 cell count &gt;500 cells/microL (HR 0.56, 95% CI 0.33-0.94). Importantly, rates of adherence and adverse effects were similar between the study groups. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similarly, in the START trial, in which 54 percent of the 4685 participants were from resource-limited settings, immediate ART initiation at CD4 cell counts &gt;500 cells/microL reduced the risk of serious illness or death (HR 0.43, 95% CI 0.30-0.62) compared with delaying ART initiation until CD4 cell count declined to ≤350 cells/microL or an AIDS event occurred [<a href="#rid43">43</a>].</p><p></p><p>These findings in resource-limited settings have mirrored the evidence from resource-rich settings on the benefit of ART at higher CD4 cell counts. (See  <a class="medical medical_review" href="/z/d/html/3777.html" rel="external">"When to initiate antiretroviral therapy in persons with HIV", section on 'Universal treatment'</a>.)</p><p>Early ART additionally has the benefit of prevention of transmission. (See <a class="local">'Prevention of sexual transmission'</a> below and  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Treatment as prevention'</a>.)</p><p>In order to initiate timely ART, WHO recommends offering ART within the first seven days of an HIV diagnosis [<a href="#rid7">7</a>]. Several studies have supported the benefit and feasibility of this approach [<a href="#rid93">93-96</a>]. Nevertheless, the optimal strategy for implementation remains uncertain. As an example, in a randomized trial of 278 newly diagnosed individuals in Lesotho, same day ART initiation with a 30-day supply at home improved health facility linkage to care at three months (69 versus 43 percent) and virologic suppression at 12 months (50 versus 34 percent) compared with routine health facility referral for ART initiation [<a href="#rid95">95</a>]. However, those rates were still unacceptably low, and many trial participants experienced treatment interruption, putting them at risk for drug-resistant HIV. Further study is warranted to identify successful approaches, which may differ by location, patient population, and ART regimen utilized.</p><p class="headingAnchor" id="H1038347"><span class="h1">IMPACT OF ART ON TRANSMISSION</span></p><p class="headingAnchor" id="H7722013"><span class="h2">ART for people with HIV</span></p><p class="headingAnchor" id="H1036417489"><span class="h3">Prevention of sexual transmission</span><span class="headingEndMark"> — </span>Reduction in transmission is a key reason for the World Health Organization (WHO) recommendation for antiretroviral therapy (ART) initiation in all individuals with HIV. High plasma HIV RNA concentrations are associated with an increased risk of HIV transmission through sexual intercourse [<a href="#rid97">97</a>]. Achieving undetectable HIV RNA with ART effectively eliminates the risk of transmission of HIV to sexual partners. This concept and the studies demonstrating it are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Treatment as prevention'</a>.)</p><p class="headingAnchor" id="H1036417495"><span class="h3">Prevention of mother-to-child transmission</span><span class="headingEndMark"> — </span>The use of ART among pregnant and breastfeeding women with HIV is a critical intervention to reduce the rates of vertical transmission of HIV to their infants. This is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13970.html" rel="external">"Prevention of HIV transmission during breastfeeding in resource-limited settings"</a>.) </p><p class="headingAnchor" id="H7722086"><span class="h2">Pre-exposure prophylaxis</span><span class="headingEndMark"> — </span>For people at substantial risk of HIV infection, the WHO recommends pre-exposure prophylaxis (PrEP) with an oral regimen containing tenofovir as part of an HIV prevention strategy [<a href="#rid6">6</a>]. The WHO also endorses the dapivirine vaginal ring, if available, as an additional choice for HIV prevention in settings with substantial HIV risk [<a href="#rid15">15</a>]. It defines "substantial risk" as an HIV incidence greater than 3 per 100 person-years, which was the lower range of the incidence among the control groups of the various trials evaluating PrEP. </p><p>Despite the need for more data to inform the optimal approach, PrEP with daily tenofovir-emtricitabine appears to be an effective strategy for preventing HIV infection in high-risk uninfected people who are committed to medication adherence and close follow-up. Several trials in various high-risk populations, including men who have sex with men, heterosexual individuals with a partner with HIV, heterosexual individuals in areas of high HIV prevalence, and people who use injection drugs, have demonstrated a reduction in the risk of HIV infection by 48 to 75 percent with daily use of tenofovir-emtricitabine compared with placebo [<a href="#rid98">98-101</a>]. A separate trial in African women that did not show efficacy of tenofovir-emtricitabine in reducing the risk of HIV infection may have been substantially limited by non-adherence [<a href="#rid102">102</a>], but subsequent open-label continuation studies demonstrated improved efficacy [<a href="#rid103">103,104</a>]. Trials of a monthly dapivirine vaginal ring suggested modest reductions in HIV incidence, although these were limited by poor adherence among participants; other analyses suggested greater efficacy among those who were highly adherent to the product [<a href="#rid103">103-106</a>]. These studies are discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis", section on 'Novel approaches to treatment'</a>.)</p><p>In cost-effectiveness analyses of PrEP, the use of oral or vaginal prophylaxis for prevention of new HIV infections in sub-Saharan Africa has been demonstrated to be cost effective, given the high prevalence of HIV and reported efficacy of PrEP from clinical trials [<a href="#rid107">107-109</a>]. However, PrEP remains costly, and the feasibility of scaling up PrEP in resource-limited settings remains to be determined, especially in light of the ongoing and unmet need for immediate ART for eligible people with HIV.</p><p class="headingAnchor" id="H12409111"><span class="h1">COST AND COST-EFFECTIVENESS</span><span class="headingEndMark"> — </span>Despite the increase in costs associated with HIV treatment, the cost-effectiveness of ART in resource-limited settings has been well demonstrated. Mathematical models of ART in Côte d'Ivoire and in India demonstrated substantial life expectancy benefits and favorable cost-effectiveness ratios [<a href="#rid110">110,111</a>]. Modeling studies [<a href="#rid112">112,113</a>] have suggested that earlier initiation of ART is associated with better outcomes in resource-limited settings and is cost-effective. (See <a class="local">'Ongoing challenges'</a> below.) </p><p class="headingAnchor" id="H12409118"><span class="h1">ACCESSIBILITY OF LABORATORY TESTING</span><span class="headingEndMark"> — </span>In resource-rich countries, routine monitoring is standard of care for both drug-related adverse events and ART efficacy (ie, immunologic and virologic responses). In contrast, the optimal strategy for monitoring people on ART in resource-limited settings remains the subject of much debate given the costs of and limited access to CD4 cell count and HIV RNA testing [<a href="#rid114">114-116</a>].</p><p class="headingAnchor" id="H8959134"><span class="h2">Adverse events</span><span class="headingEndMark"> — </span>Monitoring for ART-related adverse laboratory events in resource-limited settings is impeded<strong> </strong>by reduced accessibility to health care providers and limited testing facilities [<a href="#rid117">117</a>]. Cost considerations must also be weighed against the benefit of routine laboratory monitoring in clinical management: </p><p class="bulletIndent1"><span class="glyph">●</span>In a multisite randomized trial in Uganda and Zimbabwe (the DART Trial), 3321 ART-naïve people with HIV and CD4 ≤200 cells/microL were randomly assigned to routine laboratory monitoring after ART initiation (ie, every three months) versus clinically-driven monitoring. Mortality, progression of HIV, and serious adverse events were monitored as endpoints; clinically-driven monitoring was found to be noninferior to routine monitoring for drug toxicity [<a href="#rid118">118</a>]. However, greater disease progression among patients in the clinically-monitored group, and earlier switches to second-line therapy in the laboratory monitored group, suggested an overall beneficial impact of CD4 cell count testing.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A cohort study of 1800 people on ART in Haiti found that routine laboratory monitoring was cost-effective for assessing anemia before treatment and during therapy with <a class="drug drug_general" data-topicid="10053" href="/z/d/drug information/10053.html" rel="external">zidovudine</a>; however, routine monitoring of liver or renal function had no impact on overall patient care in this population [<a href="#rid119">119</a>]. </p><p></p><p class="headingAnchor" id="H8959141"><span class="h2">ART efficacy</span><span class="headingEndMark"> — </span>The World Health Organization (WHO) recommends routine CD4 cell count monitoring in people with HIV every 6 to 12 months following diagnosis [<a href="#rid6">6,15</a>]. Additionally, HIV RNA monitoring should be performed and reviewed by 6 months following antiretroviral therapy (ART) initiation and every 12 months thereafter in order to detect treatment failure (defined as persistently detectable viral level &gt;1000 copies/mL when tested on plasma). If HIV RNA testing is not easily available, treatment failure should be indirectly assessed through CD4 cell count and clinical monitoring, with targeted viral load testing used as a confirmatory test when available. </p><p>HIV RNA testing has not been associated with a reduction in mortality compared with CD4 cell count or clinical monitoring. However, it can detect treatment failure earlier and with greater accuracy, which is likely to translate into less accumulation of drug resistance and fewer unnecessary switches to second-line regimens. In evaluating its recommendation, the WHO performed a systematic review of studies evaluating the use of CD4 cell count and clinical monitoring for detection of treatment failure, which overall had low sensitivity and poor positive predictive value for identifying virologic failure [<a href="#rid6">6</a>]. </p><p>Multiple cost-effectiveness analyses evaluating different strategies for monitoring have been published with variable results and conclusions [<a href="#rid111">111,115,120-124</a>]. However, most suggest that CD4 monitoring is cost-effective; HIV RNA and genotype monitoring may be cost-effective depending on the setting [<a href="#rid125">125</a>]. Given that much of the costs associated with treatment failure stem from more costly second-line ART regimens, the cost-effectiveness of these monitoring approaches will likely change as alternate regimens become increasingly available and less expensive [<a href="#rid125">125,126</a>]. (See  <a class="medical medical_review" href="/z/d/html/3036.html" rel="external">"Global epidemiology of HIV infection"</a>.) </p><p class="headingAnchor" id="H1275953550"><span class="h1">IMPACT OF PROPHYLAXIS AGAINST COINFECTIONS</span></p><p class="headingAnchor" id="H2905467063"><span class="h2">Trimethoprim-sulfamethoxazole prophylaxis</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">Trimethoprim-sulfamethoxazole</a> effectively prevents opportunistic infections such as <em>Pneumocystis jirovecii</em> pneumonia and toxoplasmosis, and also effectively reduces the risk of several high-burden bacterial and parasitic infections (eg, <em>Streptococcus pneumoniae</em>, <em>Salmonella</em> species, <em>Shigella</em> species, <em>Isospora</em>, and malaria). </p><p>Early randomized trials had demonstrated reductions in morbidity and mortality with <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis among people with HIV who were not receiving ART, regardless of CD4 count [<a href="#rid127">127-129</a>]. Even in the setting of ART use, trimethoprim-sulfamethoxazole prophylaxis is associated with large reductions in mortality in observational studies from malarial and nonmalarial regions [<a href="#rid130">130,131</a>]. </p><p>Concerns have been raised regarding the development of <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> resistance among bacterial and <em>Plasmodium falciparum</em> isolates with the use of chronic prophylaxis for people with HIV. Although some studies have demonstrated increased rates of resistance [<a href="#rid132">132</a>], no data yet suggest an increased rate of clinical failure with trimethoprim-sulfamethoxazole treatment or increased rates of resistance to antimicrobials other than trimethoprim-sulfamethoxazole in communities with high rates of prophylaxis [<a href="#rid132">132-134</a>].</p><p class="headingAnchor" id="H4197020339"><span class="h2">Enhanced prophylaxis</span><span class="headingEndMark"> — </span>Severe bacterial infection, tuberculosis, and cryptococcal meningitis are major causes of morbidity and mortality among individuals with HIV in resource-limited settings. Antimicrobial prophylaxis to prevent these infections appears to reduce mortality in people with advanced HIV. </p><p>In a randomized trial in sub-Saharan Africa (Kenya, Malawi, Uganda, and Zimbabwe), over 1800 adults and children with HIV who were initiating ART and had a CD4 cell count &lt;100 cells/microL were randomly assigned to receive standard <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a> prophylaxis or enhanced prophylaxis with trimethoprim-sulfamethoxazole, <a class="drug drug_general" data-topicid="8577" href="/z/d/drug information/8577.html" rel="external">isoniazid</a> and pyridoxine for 12 weeks (or longer depending on national guidelines), <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> for 12 weeks, <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for 5 days, and a single dose of <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a> [<a href="#rid135">135</a>]. All patients were evaluated for active tuberculosis prior to enrollment and initiated on anti-tuberculous therapy if appropriate. Participants assigned to standard prophylaxis also received isoniazid prophylaxis starting at 12 weeks if indicated based on national guidelines. At 24 weeks, all-cause mortality was lower with enhanced prophylaxis compared with standard prophylaxis (8.9 versus 12.2 percent, hazard ratio 0.73, 95% CI 0.55-0.98), and the benefit was sustained at 48 weeks. Enhanced prophylaxis was also associated with lower rates of the World Health Organization (WHO) stage 3 or 4 clinical events (<a class="graphic graphic_table graphicRef55105" href="/z/d/graphic/55105.html" rel="external">table 1</a>), new tuberculosis diagnoses, cryptococcal infection, candidiasis, and new hospitalization. Despite the higher pill burden with enhanced prophylaxis, rates of self-reported ART adherence, virologic suppression, and drug-related serious adverse events were comparable across the two groups. </p><p>Results from this study, in part, informed WHO recommendations for a package of prophylactic interventions for people with advanced HIV (see <a class="local">'Prevention of coinfections'</a> above) [<a href="#rid7">7</a>]. These recommendations, however, did not include universal <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> or <a class="drug drug_general" data-topicid="9371" href="/z/d/drug information/9371.html" rel="external">albendazole</a>, because there was insufficient evidence to support the independent benefit of these individual interventions. Furthermore, the recommendations do not support primary prophylaxis with <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (without prior screening for cryptococcal infection and evaluation for meningitis) because of concerns of cost, risk of fluconazole resistance, and potential for fetal toxicity if administered to women of child-bearing potential. </p><p>Other studies have suggested a benefit to screening and early treatment for cryptococcal and latent tuberculosis infection, which are included in the WHO-recommended prophylaxis package. These data are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Screening and treatment of early infection'</a> and  <a class="medical medical_review" href="/z/d/html/8011.html" rel="external">"Treatment of tuberculosis infection (latent tuberculosis) in nonpregnant adults with HIV infection", section on 'Whom to treat'</a>.)</p><p class="headingAnchor" id="H12409132"><span class="h1">ONGOING CHALLENGES</span><span class="headingEndMark"> — </span>With the increasing availability of ART, it is essential to determine the most effective features of ART programs in order to target further interventions and to combat the clinical problems unique to developing countries.</p><p class="headingAnchor" id="H12409139"><span class="h2">HIV diagnostic testing</span><span class="headingEndMark"> — </span>Delayed HIV diagnosis reduces the survival benefit from ART, and the association between poorer outcomes and advanced immunosuppression is clear [<a href="#rid136">136</a>]. Many people who are diagnosed and enrolled in ART programs die prior to initiating ART or soon thereafter [<a href="#rid137">137,138</a>], emphasizing the need for ongoing efforts for earlier diagnostic testing [<a href="#rid139">139</a>].</p><p>Despite current World Health Organization (WHO) guidelines for earlier initiation of treatment, many people are substantially immunosuppressed at the time of diagnosis, and thus are at high risk for early mortality [<a href="#rid140">140</a>]. Substantial improvement has been observed in several high-burden countries [<a href="#rid141">141,142</a>], but improved access to HIV testing and ART initiation remains a global challenge.</p><p class="headingAnchor" id="H12409160"><span class="h2">Linkage to care and access</span><span class="headingEndMark"> — </span>Access to care is also affected by community attitudes and stigma towards HIV status and misperceptions regarding HIV risk and treatment [<a href="#rid143">143,144</a>]. Additional barriers include poor coordination of services, reduced educational level, cost of treatment, food insecurity, and transportation [<a href="#rid37">37,138,145-148</a>]. Lower baseline CD4 counts and unemployment have also been associated with poor rates of linkage to care [<a href="#rid149">149</a>]. HIV infection is often diagnosed earlier among females than males because of prenatal testing [<a href="#rid150">150</a>].</p><p class="headingAnchor" id="H12409167"><span class="h2">Retention in care and loss to follow-up</span><span class="headingEndMark"> — </span>A critical aspect of HIV treatment is the need for long-term care. Of people who start ART, between 20 and 60 percent are lost to follow-up within one year [<a href="#rid144">144,151,152</a>]. As ART program uptake increases, so do the numbers who fail to return [<a href="#rid153">153</a>].</p><p>Loss to follow-up has been associated with poor adherence, older age, advanced immunosuppression, low weight, and pregnancy [<a href="#rid37">37,145,151,154-157</a>]. High rates of death have been reported among those lost to follow-up who could be subsequently tracked [<a href="#rid158">158,159</a>]. Early morbidity related to drug toxicity or opportunistic infections may also contribute to loss to follow-up [<a href="#rid160">160</a>]. Potential interventions include provision of free care, better record-keeping to track patient visits, and the incorporation of ancillary services (eg, peer support groups and outreach services) [<a href="#rid145">145,155,161-163</a>].</p><p class="headingAnchor" id="H4941420"><span class="h2">Adherence to ART</span><span class="headingEndMark"> — </span>Antiretroviral therapy (ART) adherence in resource-limited settings is similar or superior to reported data from the United States and Europe, depending on setting and method of measurement [<a href="#rid37">37,143,164</a>].</p><p>Reasons for poor adherence in resource-limited settings are frequently related to cost of care [<a href="#rid143">143</a>] and food insecurity [<a href="#rid148">148</a>]. Adherence can also be negatively affected by concerns about stigma within the community, chronic alcohol abuse, and complicated medication regimens [<a href="#rid143">143</a>].</p><p>Several studies in various African countries have demonstrated a lower rate of attrition and higher rates of viral suppression if medications are offered free of charge [<a href="#rid145">145,155</a>]. Novel ART delivery models such as adherence clubs and decentralized medication delivery have had varied effects on adherence rates, patient retention and viral suppression [<a href="#rid165">165</a>]. </p><p>Adherence remains an important predictor of long-term success with ART. In a cohort of 207 people on ART for two years in South Africa, those with poor initial adherence to ART also had a more rapid progression to virologic failure (hazard ratio 2.82, 95% CI 1.19-6.66) [<a href="#rid166">166</a>].</p><p class="headingAnchor" id="H4941503"><span class="h2">Drug resistance</span><span class="headingEndMark"> — </span>Due to cost considerations and lack of availability, drug resistance testing is not currently recommended as part of routine HIV management by the WHO and is generally not performed in resource-limited settings. The WHO does recommend performing periodic surveys of HIV drug resistance to better inform national ART policy [<a href="#rid167">167</a>]. (See <a class="local">'Regimen selection'</a> above.)</p><p>High rates of drug resistance have been reported in people starting ART and experiencing virologic failure on ART:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and nucleoside reverse transcriptase inhibitors (NRTIs) is a growing problem in resource-limited settings, in part because of unique challenges due to prior use single-dose <a class="drug drug_general" data-topicid="9694" href="/z/d/drug information/9694.html" rel="external">nevirapine</a> (and other prevention of mother-to-child transmission (PMTCT) therapies interrupted at birth), use of regimens that may be more vulnerable to resistance, and increased prevalence of HIV subtype C, which is associated with more tenofovir resistance [<a href="#rid142">142,168</a>]. In a systematic review of studies and surveillance reports of antiretroviral resistance in resource-limited settings, the prevalence of genotypes with at least one drug resistance mutation among treatment-naïve individuals increased to 3.7 and 7.4 percent in southern and eastern Africa, respectively, over the five to nine years following rollout of national ART programs [<a href="#rid169">169</a>]. NNRTI resistance mutations (eg, K103N) were most common. Subsequent surveys have indicated continued increases in drug resistance with some countries reporting baseline resistance rates up to 25 percent [<a href="#rid170">170-172</a>].</p><p></p><p class="bulletIndent1">According to a 2017 WHO report, 6 of 11 countries that conducted national surveys on drug resistance reported &gt;10 percent prevalence of pretreatment NNRTI drug resistance in individuals starting first-line ART, which was associated with prior exposure to antiretroviral agents [<a href="#rid167">167</a>]. Other common mutations include the M184V mutation (conferring resistance to <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> and <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a>) and K65R (conferring resistance to tenofovir) [<a href="#rid173">173-175</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among people treated with an NNRTI-based regimen, the risk of drug resistance in the setting of virologic failure may be considerable [<a href="#rid176">176-181</a>]. In an international study of 1926 patients who experienced treatment failure after tenofovir plus <a class="drug drug_general" data-topicid="9544" href="/z/d/drug information/9544.html" rel="external">lamivudine</a> or <a class="drug drug_general" data-topicid="8594" href="/z/d/drug information/8594.html" rel="external">emtricitabine</a> plus an NNRTI, the prevalence of mutations associated with tenofovir resistance ranged from 20 to 60 percent, depending on the geographic regimen, with the highest prevalence in sub-Saharan Africa [<a href="#rid180">180</a>]. The prevalence of mutations associated with NNRTI resistance ranged from 42 to 82 percent. Nevertheless, at least one study suggested that NRTIs retain important efficacy in a second-line regimen despite prior high levels of NRTI resistance. Specifically, in trial from sub-Saharan Africa, 1277 individuals with HIV who had failed treatment with a first-line regimen of an NNRTI plus two NRTIs were randomly assigned to subsequent treatment with a boosted protease inhibitor plus two or three clinician-chosen NRTIs, a boosted protease inhibitor plus <a class="drug drug_general" data-topicid="9451" href="/z/d/drug information/9451.html" rel="external">raltegravir</a>, or boosted protease inhibitor monotherapy (after three months of combination therapy with raltegravir) [<a href="#rid16">16</a>]. At 96 weeks, viral load &lt;1000 copies/mL was achieved in 88 and 87 percent of the patients in the NRTI and raltegravir groups, respectively, but only 67 percent in the protease inhibitor monotherapy group.</p><p></p><p class="bulletIndent1">Among people treated with second-line ART, the risk of drug resistance may be different [<a href="#rid54">54,182</a>]. In a study from South Africa of 43 people with HIV and confirmed virologic failure on second-line ART, 67 percent still had wild-type virus. This finding suggests that poor adherence instead of resistance was contributing to failure and may be a result of the different genetic barriers to resistance for protease inhibitors [<a href="#rid54">54</a>]. Additional data are needed to determine the etiologies of ART failure, the patterns of drug resistance to different regimens, and the rates and outcomes of people with resistant virus [<a href="#rid176">176,177</a>]. (See  <a class="medical medical_review" href="/z/d/html/3772.html" rel="external">"Interpretation of HIV drug resistance testing"</a>.)</p><p></p><p>Overall, <a class="drug drug_general" data-topicid="90345" href="/z/d/drug information/90345.html" rel="external">dolutegravir</a> resistance is uncommon, although strategies for evaluating for such resistance in resource-limited settings are uncertain. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach", section on 'Commonly used agents'</a>.)</p><p class="headingAnchor" id="H7722205"><span class="h2">Test and treat</span><span class="headingEndMark"> — </span>Given the established efficacy of ART in reducing transmission of HIV among serodiscordant couples [<a href="#rid92">92</a>], there is substantial interest in the evaluation of earlier treatment as a feasible and cost-effective public health strategy to reduce community HIV incidence. One proposal that has sparked interest is that of high-coverage, community voluntary HIV testing with prompt initiation of ART at the time of diagnosis, also known as "test and treat." Mathematical models have predicted a wide range of effectiveness and costs that would result from implementation of such a policy [<a href="#rid183">183-185</a>]. Several large, randomized trials evaluating the test-and-treat strategy have demonstrated modest or no decrease in HIV incidence compared with standard of care [<a href="#rid186">186-189</a>], although this may reflect marked improvements in viral suppression with evolving standard of care. The test-and-treat strategy to prevent HIV infection is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Test and treat'</a>.)</p><p class="headingAnchor" id="H4941580"><span class="h2">Costs</span><span class="headingEndMark"> — </span>Costs of ART and laboratory monitoring remain an ongoing and increasing concern given the greater number of people receiving ART and the need to expand the capacity of treatment programs so that all people can access ART when needed. The increased availability of generic drugs in Guyana, Haiti, Vietnam, and 13 African countries has led to increased procurement of monthly medication packs (from 6 million in 2005 to 22 million in 2008) and to an estimated cost savings of more than 323 million dollars over a four-year period (2005 to 2008) [<a href="#rid190">190</a>]. Cost issues are becoming increasingly important with the demonstration that initiation of therapy earlier in the course of disease results in improved clinical outcomes, highlighting the importance of prioritizing the choice and timing of ART regimens.</p><p>Another challenge is to expand effective treatment to people who cannot tolerate first-line regimens because of either toxicity or virologic failure and resistance. Second-line regimens are available in many countries [<a href="#rid163">163</a>], although at considerable increased cost (up to five times that of first-line medications) [<a href="#rid191">191</a>]. Cost-effective algorithms to guide regimen changes for treatment failure remain a subject of debate [<a href="#rid126">126,192</a>].</p><p>Concerns regarding funding for international ART programs persist, and debate continues regarding allocation of resources and use of available funds [<a href="#rid193">193,194</a>].</p><p class="headingAnchor" id="H3276743499"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111624.html" rel="external">"Society guideline links: HIV treatment in nonpregnant adults and adolescents"</a>.)</p><p class="headingAnchor" id="H12409174"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>The World Health Organization (WHO) recommends initiation of antiretroviral therapy (ART) in all people with HIV, regardless of CD4 cell count or clinical stage. The use of ART has dramatically reduced both morbidity and mortality for those with HIV/AIDS in resource-limited settings. The benefit of ART is substantial even at high CD4 cell counts. Successful ART for infected individuals also reduces the risk of transmission. (See <a class="local">'Recommendations from the World Health Organization'</a> above and <a class="local">'Optimal timing of ART'</a> above and  <a class="medical medical_review" href="/z/d/html/16612.html" rel="external">"HIV infection: Risk factors and prevention strategies", section on 'Treatment as prevention'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>ART, with secondary immune reconstitution, also decreases the incidence of other prevalent coinfections in patients with HIV, such as malaria, tuberculosis, and cryptococcus. Prophylaxis against these and other coinfections is associated with additional mortality benefit and is recommended for certain populations with HIV (<a class="graphic graphic_algorithm graphicRef117438" href="/z/d/graphic/117438.html" rel="external">algorithm 1</a>). (See <a class="local">'Effect of ART on other comorbidities'</a> above and <a class="local">'Prevention of coinfections'</a> above and <a class="local">'Impact of prophylaxis against coinfections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The WHO recommends pre-exposure prophylaxis with an oral tenofovir-containing regimen for individuals without HIV at substantial risk for infection. Pre-exposure prophylaxis with daily tenofovir-emtricitabine reduces the risk of HIV acquisition, if used with consistency. (See <a class="local">'Pre-exposure prophylaxis'</a> above and  <a class="medical medical_review" href="/z/d/html/113426.html" rel="external">"HIV pre-exposure prophylaxis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The use of ART among pregnant and breastfeeding females with HIV to prevent transmission of HIV to their infants is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3799.html" rel="external">"Prevention of vertical HIV transmission in resource-limited settings"</a> and  <a class="medical medical_review" href="/z/d/html/13970.html" rel="external">"Prevention of HIV transmission during breastfeeding in resource-limited settings"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Despite the costs associated with HIV treatment, multiple analyses have demonstrated that initiation of ART is cost effective. (See <a class="local">'Cost and cost-effectiveness'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Access to laboratory testing in many resource-limited settings continues to be limited; further investigation of clinical outcomes and cost-effectiveness of different monitoring strategies are needed. (See <a class="local">'Accessibility of laboratory testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Access to second-line ART for those who have failed first-line is increasingly available. Decreases in drug costs for second-line therapy will enhance this availability. (See <a class="local">'Costs'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>HIV testing, linkage to care, and retention in care continue to be major factors limiting the success of ART programs in many settings. (See <a class="local">'Linkage to care and access'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">UNAIDS.Global AIDS Strategy 2021-2026 — End Inequalities. End AIDS. https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy (Accessed on November 02, 2021).</li><li class="breakAll">UNAIDS. Global AIDS update: 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf (Accessed on March 21, 2021).</li><li><a class="nounderline abstract_t">Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012; 307:2060.</a></li><li class="breakAll">UNAIDS. UNAIDS Data 2020. https://www.unaids.org/sites/default/files/media_asset/2020_aids-data-book_en.pdf (Accessed on March 29, 2021).</li><li class="breakAll">Joint United Nations Programme on HIV/AIDS. The Gap Report. September 2014 http://www.unaids.org/sites/default/files/media_asset/UNAIDS_Gap_report_en.pdf (Accessed on March 21, 2021).</li><li class="breakAll">World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. http://www.who.int/hiv/pub/arv/arv-2016/en/ (Accessed on March 21, 2021).</li><li class="breakAll">World Health Organization. Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy, July 2017. http://apps.who.int/iris/bitstream/10665/255884/1/9789241550062-eng.pdf?ua=1 (Accessed on March 19, 2021).</li><li class="breakAll">World Health Organization. Update of recommendations on first- and second-line antiretroviral regimens. https://apps.who.int/iris/bitstream/handle/10665/325892/WHO-CDS-HIV-19.15-eng.pdf?ua=1 (Accessed on August 26, 2022).</li><li><a class="nounderline abstract_t">Venter WDF, Moorhouse M, Sokhela S, et al. Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV. N Engl J Med 2019; 381:803.</a></li><li><a class="nounderline abstract_t">NAMSAL ANRS 12313 Study Group, Kouanfack C, Mpoudi-Etame M, et al. Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1. N Engl J Med 2019; 381:816.</a></li><li class="breakAll">Zash R, Holmes K, Diseko M, et al. Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana. Presented at the 24th International AIDS Conference, July 2022.</li><li><a class="nounderline abstract_t">Zash R, Makhema J, Shapiro RL. Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception. N Engl J Med 2018; 379:979.</a></li><li><a class="nounderline abstract_t">Zash R, Jacobson DL, Diseko M, et al. Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study. Lancet Glob Health 2018; 6:e804.</a></li><li><a class="nounderline abstract_t">Patel K, Huo Y, Jao J, et al. Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States. N Engl J Med 2022; 387:799.</a></li><li class="breakAll">World Health Organization. Updated recommendations on HIV prevention, infant diagnosis, antiretroviral initiation and monitoring, March 2021. https://www.who.int/publications/i/item/9789240022232 (Accessed on March 29, 2021).</li><li><a class="nounderline abstract_t">Paton NI, Kityo C, Hoppe A, et al. Assessment of second-line antiretroviral regimens for HIV therapy in Africa. N Engl J Med 2014; 371:234.</a></li><li><a class="nounderline abstract_t">Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis 2019; 19:253.</a></li><li><a class="nounderline abstract_t">SECOND-LINE Study Group, Boyd MA, Kumarasamy N, et al. Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study. Lancet 2013; 381:2091.</a></li><li><a class="nounderline abstract_t">La Rosa AM, Harrison LJ, Taiwo B, et al. Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study. Lancet HIV 2016; 3:e247.</a></li><li><a class="nounderline abstract_t">Paton NI, Musaazi J, Kityo C, et al. Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV. N Engl J Med 2021; 385:330.</a></li><li><a class="nounderline abstract_t">Paton NI, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV 2022; 9:e381.</a></li><li><a class="nounderline abstract_t">Siedner MJ, Moosa MS, McCluskey S, et al. Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial. Ann Intern Med 2021; 174:1683.</a></li><li class="breakAll">The World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children. http://apps.who.int/iris/bitstream/handle/10665/260399/9789241550277-eng.pdf;jsessionid=7A37044AC579D4A69EBBBF0B47BC60AF?sequence=1 (Accessed on March 19, 2021).</li><li><a class="nounderline abstract_t">Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817.</a></li><li><a class="nounderline abstract_t">Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis. Int J STD AIDS 2008; 19:291.</a></li><li><a class="nounderline abstract_t">Mills EJ, Bakanda C, Birungi J, et al. Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda. Ann Intern Med 2011; 155:209.</a></li><li><a class="nounderline abstract_t">Mills EJ, Bakanda C, Birungi J, et al. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda. AIDS 2011; 25:851.</a></li><li><a class="nounderline abstract_t">Severe P, Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257.</a></li><li><a class="nounderline abstract_t">Toure S, Kouadio B, Seyler C, et al. Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants. AIDS 2008; 22:873.</a></li><li><a class="nounderline abstract_t">Madec Y, Laureillard D, Pinoges L, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS 2007; 21:351.</a></li><li><a class="nounderline abstract_t">Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360:119.</a></li><li><a class="nounderline abstract_t">Hargrove JW, Humphrey JH, ZVITAMBO Study Group. Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe. AIDS 2010; 24:F11.</a></li><li><a class="nounderline abstract_t">Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA 2006; 296:782.</a></li><li><a class="nounderline abstract_t">Lawn SD, Harries AD, Anglaret X, et al. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897.</a></li><li><a class="nounderline abstract_t">Walker AS, Prendergast AJ, Mugyenyi P, et al. Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe. Clin Infect Dis 2012; 55:1707.</a></li><li><a class="nounderline abstract_t">Gupta A, Nadkarni G, Yang WT, et al. Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 2011; 6:e28691.</a></li><li><a class="nounderline abstract_t">Karcher H, Omondi A, Odera J, et al. Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 2007; 12:687.</a></li><li><a class="nounderline abstract_t">Johannessen A, Naman E, Ngowi BJ, et al. Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 2008; 8:52.</a></li><li><a class="nounderline abstract_t">Boulle A, Bock P, Osler M, et al. Antiretroviral therapy and early mortality in South Africa. Bull World Health Organ 2008; 86:678.</a></li><li><a class="nounderline abstract_t">Fox MP, Sanne IM, Conradie F, et al. Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS 2010; 24:2041.</a></li><li><a class="nounderline abstract_t">TEMPRANO ANRS 12136 Study Group, Danel C, Moh R, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med 2015; 373:808.</a></li><li><a class="nounderline abstract_t">Nash D, Katyal M, Brinkhof MW, et al. Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies. AIDS 2008; 22:2291.</a></li><li><a class="nounderline abstract_t">INSIGHT START Study Group, Lundgren JD, Babiker AG, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med 2015; 373:795.</a></li><li><a class="nounderline abstract_t">Hoffmann CJ, Fielding KL, Johnston V, et al. Changing predictors of mortality over time from cART start: implications for care. J Acquir Immune Defic Syndr 2011; 58:269.</a></li><li><a class="nounderline abstract_t">Bor J, Herbst AJ, Newell ML, Bärnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339:961.</a></li><li><a class="nounderline abstract_t">Cornell M, Schomaker M, Garone DB, et al. Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study. PLoS Med 2012; 9:e1001304.</a></li><li><a class="nounderline abstract_t">Dou Z, Xu J, Jiao JH, et al. Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008. PLoS One 2011; 6:e22707.</a></li><li><a class="nounderline abstract_t">Druyts E, Dybul M, Kanters S, et al. Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis. AIDS 2013; 27:417.</a></li><li><a class="nounderline abstract_t">Pujades-Rodríguez M, Balkan S, Arnould L, et al. Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries. JAMA 2010; 304:303.</a></li><li><a class="nounderline abstract_t">Fox MP, Ive P, Long L, et al. High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa. J Acquir Immune Defic Syndr 2010; 53:500.</a></li><li><a class="nounderline abstract_t">Win MM, Maek-A-Nantawat W, Phonrat B, et al. Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand. J Int Assoc Physicians AIDS Care (Chic) 2011; 10:57.</a></li><li><a class="nounderline abstract_t">Murphy RA, Sunpath H, Castilla C, et al. Second-line antiretroviral therapy: long-term outcomes in South Africa. J Acquir Immune Defic Syndr 2012; 61:158.</a></li><li><a class="nounderline abstract_t">Bartlett JA, Ribaudo HJ, Wallis CL, et al. Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings. AIDS 2012; 26:1345.</a></li><li><a class="nounderline abstract_t">Levison JH, Orrell C, Gallien S, et al. Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa. PLoS One 2012; 7:e32144.</a></li><li><a class="nounderline abstract_t">Wood R, Middelkoop K, Myer L, et al. Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control. Am J Respir Crit Care Med 2007; 175:87.</a></li><li><a class="nounderline abstract_t">Bassett IV, Wang B, Chetty S, et al. Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823.</a></li><li><a class="nounderline abstract_t">Oni T, Burke R, Tsekela R, et al. High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 2011; 66:669.</a></li><li><a class="nounderline abstract_t">Koenig SP, Riviere C, Leger P, et al. High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy. Clin Infect Dis 2009; 48:829.</a></li><li><a class="nounderline abstract_t">Kranzer K, Houben RM, Glynn JR, et al. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:93.</a></li><li><a class="nounderline abstract_t">Badri M, Wilson D, Wood R. Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. Lancet 2002; 359:2059.</a></li><li><a class="nounderline abstract_t">Golub JE, Saraceni V, Cavalcante SC, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441.</a></li><li><a class="nounderline abstract_t">Moore D, Liechty C, Ekwaru P, et al. Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda. AIDS 2007; 21:713.</a></li><li><a class="nounderline abstract_t">Sanguanwongse N, Cain KP, Suriya P, et al. Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand. J Acquir Immune Defic Syndr 2008; 48:181.</a></li><li><a class="nounderline abstract_t">El-Sadr WM, Tsiouris SJ. HIV-associated tuberculosis: diagnostic and treatment challenges. Semin Respir Crit Care Med 2008; 29:525.</a></li><li><a class="nounderline abstract_t">Lawn SD, Myer L, Bekker LG, Wood R. Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa. AIDS 2007; 21:335.</a></li><li><a class="nounderline abstract_t">Abdool Karim SS, Naidoo K, Grobler A, et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697.</a></li><li><a class="nounderline abstract_t">Blanc FX, Sok T, Laureillard D, et al. Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 2011; 365:1471.</a></li><li><a class="nounderline abstract_t">Havlir DV, Kendall MA, Ive P, et al. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med 2011; 365:1482.</a></li><li><a class="nounderline abstract_t">Török ME, Yen NT, Chau TT, et al. Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis. Clin Infect Dis 2011; 52:1374.</a></li><li><a class="nounderline abstract_t">Francesconi P, Fabiani M, Dente MG, et al. HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study. AIDS 2001; 15:2445.</a></li><li><a class="nounderline abstract_t">Whitworth J, Morgan D, Quigley M, et al. Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study. Lancet 2000; 356:1051.</a></li><li><a class="nounderline abstract_t">French N, Nakiyingi J, Lugada E, et al. Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults. AIDS 2001; 15:899.</a></li><li><a class="nounderline abstract_t">Mermin J, Ekwaru JP, Liechty CA, et al. Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 2006; 367:1256.</a></li><li><a class="nounderline abstract_t">Jongwutiwes U, Kiertiburanakul S, Sungkanuparph S. Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection. Curr HIV Res 2007; 5:355.</a></li><li><a class="nounderline abstract_t">Bisson GP, Nthobatsong R, Thakur R, et al. The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana. J Acquir Immune Defic Syndr 2008; 49:227.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Meintjes G, Harrison TS. Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa. J Infect 2010; 60:496.</a></li><li><a class="nounderline abstract_t">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291.</a></li><li><a class="nounderline abstract_t">Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251.</a></li><li><a class="nounderline abstract_t">Law WP, Duncombe CJ, Mahanontharit A, et al. Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort. AIDS 2004; 18:1169.</a></li><li><a class="nounderline abstract_t">Idoko J, Meloni S, Muazu M, et al. Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 2009; 49:1268.</a></li><li><a class="nounderline abstract_t">Hoffmann CJ, Charalambous S, Martin DJ, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008; 47:1479.</a></li><li><a class="nounderline abstract_t">Moore E, Beadsworth MB, Chaponda M, et al. Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. J Infect 2010; 61:155.</a></li><li><a class="nounderline abstract_t">Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008; 22:1.</a></li><li><a class="nounderline abstract_t">Wolday D, Akuffo H, Demissie A, Britton S. Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication. Infect Immun 1999; 67:5258.</a></li><li><a class="nounderline abstract_t">ter Horst R, Collin SM, Ritmeijer K, et al. Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46:1702.</a></li><li><a class="nounderline abstract_t">Piot P, Quinn TC, Taelman H, et al. Acquired immunodeficiency syndrome in a heterosexual population in Zaire. Lancet 1984; 2:65.</a></li><li><a class="nounderline abstract_t">Serwadda D, Mugerwa RD, Sewankambo NK, et al. Slim disease: a new disease in Uganda and its association with HTLV-III infection. Lancet 1985; 2:849.</a></li><li><a class="nounderline abstract_t">Casper C. The increasing burden of HIV-associated malignancies in resource-limited regions. Annu Rev Med 2011; 62:157.</a></li><li><a class="nounderline abstract_t">Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study. Int J Cancer 2006; 118:985.</a></li><li><a class="nounderline abstract_t">Dryden-Peterson S, Medhin H, Kebabonye-Pusoentsi M, et al. Cancer Incidence following Expansion of HIV Treatment in Botswana. PLoS One 2015; 10:e0135602.</a></li><li><a class="nounderline abstract_t">Mutyaba I, Phipps W, Krantz EM, et al. A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999-2008. J Acquir Immune Defic Syndr 2015; 69:481.</a></li><li><a class="nounderline abstract_t">Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365:493.</a></li><li><a class="nounderline abstract_t">Amanyire G, Semitala FC, Namusobya J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV 2016; 3:e539.</a></li><li><a class="nounderline abstract_t">Rosen S, Maskew M, Fox MP, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med 2016; 13:e1002015.</a></li><li><a class="nounderline abstract_t">Labhardt ND, Ringera I, Lejone TI, et al. Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial. JAMA 2018; 319:1103.</a></li><li><a class="nounderline abstract_t">Ford N, Migone C, Calmy A, et al. Benefits and risks of rapid initiation of antiretroviral therapy. AIDS 2018; 32:17.</a></li><li><a class="nounderline abstract_t">Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921.</a></li><li><a class="nounderline abstract_t">Grant RM, Lama JR, Anderson PL, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med 2010; 363:2587.</a></li><li><a class="nounderline abstract_t">Baeten JM, Donnell D, Ndase P, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med 2012; 367:399.</a></li><li><a class="nounderline abstract_t">Thigpen MC, Kebaabetswe PM, Paxton LA, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med 2012; 367:423.</a></li><li><a class="nounderline abstract_t">Choopanya K, Martin M, Suntharasamai P, et al. Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013; 381:2083.</a></li><li><a class="nounderline abstract_t">Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012; 367:411.</a></li><li><a class="nounderline abstract_t">Nel A, van Niekerk N, Van Baelen B, et al. Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study. Lancet HIV 2021; 8:e77.</a></li><li><a class="nounderline abstract_t">Baeten JM, Palanee-Phillips T, Mgodi NM, et al. Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study. Lancet HIV 2021; 8:e87.</a></li><li><a class="nounderline abstract_t">Nel A, van Niekerk N, Kapiga S, et al. Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women. N Engl J Med 2016; 375:2133.</a></li><li><a class="nounderline abstract_t">Baeten JM, Palanee-Phillips T, Brown ER, et al. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women. N Engl J Med 2016; 375:2121.</a></li><li><a class="nounderline abstract_t">Hallett TB, Baeten JM, Heffron R, et al. Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study. PLoS Med 2011; 8:e1001123.</a></li><li><a class="nounderline abstract_t">Walensky RP, Park JE, Wood R, et al. The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women. Clin Infect Dis 2012; 54:1504.</a></li><li><a class="nounderline abstract_t">Glaubius R, Ding Y, Penrose KJ, et al. Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness. J Int AIDS Soc 2019; 22:e25282.</a></li><li><a class="nounderline abstract_t">Freedberg KA, Kumarasamy N, Losina E, et al. Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy. AIDS 2007; 21 Suppl 4:S117.</a></li><li><a class="nounderline abstract_t">Goldie SJ, Yazdanpanah Y, Losina E, et al. Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire. N Engl J Med 2006; 355:1141.</a></li><li><a class="nounderline abstract_t">Walensky RP, Wolf LL, Wood R, et al. When to start antiretroviral therapy in resource-limited settings. Ann Intern Med 2009; 151:157.</a></li><li><a class="nounderline abstract_t">Walensky RP, Ross EL, Kumarasamy N, et al. Cost-effectiveness of HIV treatment as prevention in serodiscordant couples. N Engl J Med 2013; 369:1715.</a></li><li><a class="nounderline abstract_t">Moore DM, Awor A, Downing R, et al. CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy. J Acquir Immune Defic Syndr 2008; 49:477.</a></li><li><a class="nounderline abstract_t">Phillips AN, Pillay D, Miners AH, et al. Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model. Lancet 2008; 371:1443.</a></li><li><a class="nounderline abstract_t">Working Group on Modelling of Antiretroviral Therapy Monitoring Strategies in Sub-Saharan Africa, Phillips A, Shroufi A, et al. Sustainable HIV treatment in Africa through viral-load-informed differentiated care. Nature 2015; 528:S68.</a></li><li><a class="nounderline abstract_t">Subbaraman R, Chaguturu SK, Mayer KH, et al. Adverse effects of highly active antiretroviral therapy in developing countries. Clin Infect Dis 2007; 45:1093.</a></li><li><a class="nounderline abstract_t">DART Trial Team, Mugyenyi P, Walker AS, et al. Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial. Lancet 2010; 375:123.</a></li><li><a class="nounderline abstract_t">Koenig SP, Schackman BR, Riviere C, et al. Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting. Clin Infect Dis 2010; 51:600.</a></li><li><a class="nounderline abstract_t">Bendavid E, Young SD, Katzenstein DA, et al. Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis. Arch Intern Med 2008; 168:1910.</a></li><li><a class="nounderline abstract_t">Bishai D, Colchero A, Durack DT. The cost effectiveness of antiretroviral treatment strategies in resource-limited settings. AIDS 2007; 21:1333.</a></li><li><a class="nounderline abstract_t">Vijayaraghavan A, Efrusy MB, Mazonson PD, et al. Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world. J Acquir Immune Defic Syndr 2007; 46:91.</a></li><li><a class="nounderline abstract_t">Kimmel AD, Weinstein MC, Anglaret X, et al. Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness. J Acquir Immune Defic Syndr 2010; 54:258.</a></li><li><a class="nounderline abstract_t">Kahn JG, Marseille E, Moore D, et al. CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study. BMJ 2011; 343:d6884.</a></li><li><a class="nounderline abstract_t">Walensky RP, Ciaranello AL, Park JE, Freedberg KA. Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature. Clin Infect Dis 2010; 51:85.</a></li><li><a class="nounderline abstract_t">Levison JH, Wood R, Scott CA, et al. The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa. Clin Infect Dis 2013; 56:587.</a></li><li><a class="nounderline abstract_t">Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469.</a></li><li><a class="nounderline abstract_t">Anglaret X, Chêne G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463.</a></li><li><a class="nounderline abstract_t">Mermin J, Lule J, Ekwaru JP, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 2004; 364:1428.</a></li><li><a class="nounderline abstract_t">Hoffmann CJ, Fielding KL, Charalambous S, et al. Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS 2010; 24:1709.</a></li><li><a class="nounderline abstract_t">Walker AS, Ford D, Gilks CF, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278.</a></li><li><a class="nounderline abstract_t">Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 2008; 79:320.</a></li><li><a class="nounderline abstract_t">Malamba S, Sandison T, Lule J, et al. Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus. Am J Trop Med Hyg 2010; 82:766.</a></li><li><a class="nounderline abstract_t">Sibanda EL, Weller IV, Hakim JG, Cowan FM. Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review. Clin Infect Dis 2011; 52:1184.</a></li><li><a class="nounderline abstract_t">Hakim J, Musiime V, Szubert AJ, et al. Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa. N Engl J Med 2017; 377:233.</a></li><li><a class="nounderline abstract_t">Muyingo SK, Walker AS, Reid A, et al. Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe. J Acquir Immune Defic Syndr 2008; 48:468.</a></li><li class="breakAll">Muwanga A, Easterbrook P, Schaefer, P, et al. Losses to follow-up in a large ART program in Uganda (abstract 840). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.</li><li><a class="nounderline abstract_t">Yu JK, Chen SC, Wang KY, et al. True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi. Bull World Health Organ 2007; 85:550.</a></li><li><a class="nounderline abstract_t">Bassett IV, Walensky RP. Integrating HIV screening into routine health care in resource-limited settings. Clin Infect Dis 2010; 50 Suppl 3:S77.</a></li><li><a class="nounderline abstract_t">Siedner MJ, Ng CK, Bassett IV, et al. Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis. Clin Infect Dis 2015; 60:1120.</a></li><li><a class="nounderline abstract_t">Auld AF, Shiraishi RW, Oboho I, et al. Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment - 10 Countries, 2004-2015. MMWR Morb Mortal Wkly Rep 2017; 66:558.</a></li><li><a class="nounderline abstract_t">Grimsrud A, Cornell M, Schomaker M, et al. CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study. J Epidemiol Community Health 2016; 70:549.</a></li><li><a class="nounderline abstract_t">Mills EJ, Nachega JB, Buchan I, et al. Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis. JAMA 2006; 296:679.</a></li><li><a class="nounderline abstract_t">Geng EH, Odeny TA, Lyamuya R, et al. Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach. Clin Infect Dis 2016; 62:935.</a></li><li><a class="nounderline abstract_t">Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis 2005; 41:217.</a></li><li class="breakAll">Geng E, Bangsberg D, Musinguzi N, et al. What becomes of the defaulters? A sampling-based approach to determine outcomes of patients who become lost to follow-up in ART scale-up programs in Africa (abstract 842). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.</li><li><a class="nounderline abstract_t">Posse M, Meheus F, van Asten H, et al. Barriers to access to antiretroviral treatment in developing countries: a review. Trop Med Int Health 2008; 13:904.</a></li><li><a class="nounderline abstract_t">Weiser SD, Tuller DM, Frongillo EA, et al. Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda. PLoS One 2010; 5:e10340.</a></li><li><a class="nounderline abstract_t">Bassett IV, Wang B, Chetty S, et al. Loss to care and death before antiretroviral therapy in Durban, South Africa. J Acquir Immune Defic Syndr 2009; 51:135.</a></li><li><a class="nounderline abstract_t">ART-LINC Collaboration of International Databases to Evaluate AIDS (IeDEA), Keiser O, Anastos K, et al. Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America. Trop Med Int Health 2008; 13:870.</a></li><li><a class="nounderline abstract_t">Brinkhof MW, Dabis F, Myer L, et al. Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries. Bull World Health Organ 2008; 86:559.</a></li><li><a class="nounderline abstract_t">Amuron B, Namara G, Birungi J, et al. Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda. BMC Public Health 2009; 9:290.</a></li><li><a class="nounderline abstract_t">Fox MP, Rosen S. Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Trop Med Int Health 2010; 15 Suppl 1:1.</a></li><li><a class="nounderline abstract_t">Palombi L, Marazzi MC, Guidotti G, et al. Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clin Infect Dis 2009; 48:115.</a></li><li><a class="nounderline abstract_t">Rosen S, Fox MP, Gill CJ. Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Med 2007; 4:e298.</a></li><li class="breakAll">Wang B, Losina E, Stark R, et al. Loss to follow-up in community clinics in South Africa: role of CD4 count, gender, pregnancy (abstract 841). 15th Conference on Retroviruses and Opportunistic Infections. 2008. Boston, MA.</li><li><a class="nounderline abstract_t">Geng EH, Glidden DV, Emenyonu N, et al. Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa. Trop Med Int Health 2010; 15 Suppl 1:63.</a></li><li><a class="nounderline abstract_t">Brinkhof MW, Pujades-Rodriguez M, Egger M. Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS One 2009; 4:e5790.</a></li><li><a class="nounderline abstract_t">Chammartin F, Zürcher K, Keiser O, et al. Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis. Clin Infect Dis 2018; 67:1643.</a></li><li><a class="nounderline abstract_t">de Cherif TK, Schoeman JH, Cleary S, et al. Early severe morbidity and resource utilization in South African adults on antiretroviral therapy. BMC Infect Dis 2009; 9:205.</a></li><li><a class="nounderline abstract_t">Dalal RP, Macphail C, Mqhayi M, et al. Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa. J Acquir Immune Defic Syndr 2008; 47:101.</a></li><li><a class="nounderline abstract_t">Losina E, Touré H, Uhler LM, et al. Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal. PLoS Med 2009; 6:e1000173.</a></li><li><a class="nounderline abstract_t">Duda SN, Farr AM, Lindegren ML, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc 2014; 17:19045.</a></li><li><a class="nounderline abstract_t">Orrell C, Bangsberg DR, Badri M, Wood R. Adherence is not a barrier to successful antiretroviral therapy in South Africa. AIDS 2003; 17:1369.</a></li><li><a class="nounderline abstract_t">Fox MP, Pascoe S, Huber AN, et al. Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa. PLoS Med 2019; 16:e1002874.</a></li><li><a class="nounderline abstract_t">Ford N, Darder M, Spelman T, et al. Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort. PLoS One 2010; 5:e10460.</a></li><li class="breakAll">World Health Organization. Global action plan on HIV drug resistance 2017-2021. July 2017. http://apps.who.int/iris/bitstream/handle/10665/255883/9789241512848-eng.pdf;jsessionid=5655D83FDD552A51922A57E4DAB66F4D?sequence=1 (Accessed on March 21, 2021).</li><li><a class="nounderline abstract_t">Milne RS, Silverman RA, Beck IA, et al. Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women. AIDS 2019; 33:941.</a></li><li><a class="nounderline abstract_t">Gupta RK, Jordan MR, Sultan BJ, et al. Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis. Lancet 2012; 380:1250.</a></li><li><a class="nounderline abstract_t">Gupta RK, Gregson J, Parkin N, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis. Lancet Infect Dis 2018; 18:346.</a></li><li><a class="nounderline abstract_t">Ngo-Giang-Huong N, Huynh THK, Dagnra AY, et al. Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries. J Antimicrob Chemother 2019; 74:462.</a></li><li><a class="nounderline abstract_t">Ávila-Ríos S, García-Morales C, Valenzuela-Lara M, et al. HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey. J Antimicrob Chemother 2019; 74:1044.</a></li><li><a class="nounderline abstract_t">Barth RE, van der Loeff MF, Schuurman R, et al. Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review. Lancet Infect Dis 2010; 10:155.</a></li><li><a class="nounderline abstract_t">Orrell C, Walensky RP, Losina E, et al. HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme. Antivir Ther 2009; 14:523.</a></li><li><a class="nounderline abstract_t">Hamers RL, Sigaloff KC, Wensing AM, et al. Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies. Clin Infect Dis 2012; 54:1660.</a></li><li><a class="nounderline abstract_t">Murphy RA, Sunpath H, Lu Z, et al. Outcomes after virologic failure of first-line ART in South Africa. AIDS 2010; 24:1007.</a></li><li><a class="nounderline abstract_t">Hosseinipour MC, van Oosterhout JJ, Weigel R, et al. The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy. AIDS 2009; 23:1127.</a></li><li><a class="nounderline abstract_t">Marconi VC, Sunpath H, Lu Z, et al. Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa. Clin Infect Dis 2008; 46:1589.</a></li><li><a class="nounderline abstract_t">Wallis CL, Aga E, Ribaudo H, et al. Drug susceptibility and resistance mutations after first-line failure in resource limited settings. Clin Infect Dis 2014; 59:706.</a></li><li><a class="nounderline abstract_t">TenoRes Study Group. Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study. Lancet Infect Dis 2016; 16:565.</a></li><li><a class="nounderline abstract_t">Bachmann N, von Braun A, Labhardt ND, et al. Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland. J Antimicrob Chemother 2019; 74:468.</a></li><li><a class="nounderline abstract_t">Hosseinipour MC, Gupta RK, Van Zyl G, et al. Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings. J Infect Dis 2013; 207 Suppl 2:S49.</a></li><li><a class="nounderline abstract_t">Granich RM, Gilks CF, Dye C, et al. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373:48.</a></li><li><a class="nounderline abstract_t">Walensky RP, Paltiel AD, Losina E, et al. Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC. Clin Infect Dis 2010; 51:392.</a></li><li><a class="nounderline abstract_t">Dodd PJ, Garnett GP, Hallett TB. Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings. AIDS 2010; 24:729.</a></li><li><a class="nounderline abstract_t">Iwuji CC, Orne-Gliemann J, Larmarange J, et al. Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial. Lancet HIV 2018; 5:e116.</a></li><li><a class="nounderline abstract_t">Makhema J, Wirth KE, Pretorius Holme M, et al. Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana. N Engl J Med 2019; 381:230.</a></li><li><a class="nounderline abstract_t">Havlir DV, Balzer LB, Charlebois ED, et al. HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa. N Engl J Med 2019; 381:219.</a></li><li><a class="nounderline abstract_t">Hayes RJ, Donnell D, Floyd S, et al. Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART). N Engl J Med 2019; 381:207.</a></li><li><a class="nounderline abstract_t">Holmes CB, Coggin W, Jamieson D, et al. Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs. JAMA 2010; 304:313.</a></li><li class="breakAll">Clinton Health Access. 2015 Antiretroviral (ARV) chai reference price list. http://www.clintonhealthaccess.org/content/uploads/2016/01/2015-CHAI-ARV-Reference-Price-List.pdf (Accessed on March 19, 2021).</li><li><a class="nounderline abstract_t">Rosen S, Long L, Sanne I, et al. The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data. J Int AIDS Soc 2011; 14:24.</a></li><li class="breakAll">No time to quit: HIV/AIDS treatment gap widening in Africa. http://www.doctorswithoutborders.org/publications/reports/2010/MSF-No-Time-to-Quit-HIV-AIDS.pdf (Accessed on March 19, 2021).</li><li><a class="nounderline abstract_t">Voelker R. One casualty of global economic crisis: uncertain finances for HIV/AIDS programs. JAMA 2010; 304:259.</a></li></ol></div><div id="topicVersionRevision">Topic 13980 Version 50.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : UNAIDS.Global AIDS Strategy 2021-2026 — End Inequalities. End AIDS. https://www.unaids.org/en/resources/documents/2021/2021-2026-global-AIDS-strategy (Accessed on November 02, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : UNAIDS. Global AIDS update: 2016. http://www.unaids.org/sites/default/files/media_asset/global-AIDS-update-2016_en.pdf (Accessed on March 21, 2021).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22665105" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : HIV development assistance and adult mortality in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339677" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Dolutegravir plus Two Different Prodrugs of Tenofovir to Treat HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339676" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31339676" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Dolutegravir-Based or Low-Dose Efavirenz-Based Regimen for the Treatment of HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30037297" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Neural-Tube Defects with Dolutegravir Treatment from the Time of Conception.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29880310" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Comparative safety of dolutegravir-based or efavirenz-based antiretroviral treatment started during pregnancy in Botswana: an observational study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36053505" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36053505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Dolutegravir in Pregnancy as Compared with Current HIV Regimens in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25014688" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Assessment of second-line antiretroviral regimens for HIV therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30732940" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769235" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Ritonavir-boosted lopinavir plus nucleoside or nucleotide reverse transcriptase inhibitors versus ritonavir-boosted lopinavir plus raltegravir for treatment of HIV-1 infection in adults with virological failure of a standard first-line ART regimen (SECOND-LINE): a randomised, open-label, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27240787" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Raltegravir in second-line antiretroviral therapy in resource-limited settings (SELECT): a randomised, phase 3, non-inferiority study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34289276" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Dolutegravir or Darunavir in Combination with Zidovudine or Tenofovir to Treat HIV.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35460601" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34698502" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34698502" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Resistance Testing for Management of HIV Virologic Failure in Sub-Saharan Africa : An Unblinded Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16530575" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482957" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures -- a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21768555" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Life expectancy of persons receiving combination antiretroviral therapy in low-income countries: a cohort analysis from Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21330903" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20647201" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Early versus standard antiretroviral therapy for HIV-infected adults in Haiti.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18427206" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Rapid scaling-up of antiretroviral therapy in 10,000 adults in Côte d'Ivoire: 2-year outcomes and determinants.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255742" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12126821" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20095074" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Mortality among HIV-positive postpartum women with high CD4 cell counts in Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16905784" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784453" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22972859" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Mortality in the year following antiretroviral therapy initiation in HIV-infected adults and children in Uganda and Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22220193" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17445136" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18430196" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18797643" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Antiretroviral therapy and early mortality in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20613459" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26193126" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18981768" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Long-term immunologic response to antiretroviral therapy in low-income countries: a collaborative analysis of prospective studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26192873" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21876447" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Changing predictors of mortality over time from cART start: implications for care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23430655" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22973181" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Gender differences in survival among adult patients starting antiretroviral therapy in South Africa: a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21857947" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Gender difference in 2-year mortality and immunological response to ART in an HIV-infected Chinese population, 2006-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22948271" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Male sex and the risk of mortality among individuals enrolled in antiretroviral therapy programs in Africa: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639564" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19838128" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21368017" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Virologic and Immunologic Outcomes of the Second-Line Regimens of Antiretroviral Therapy Among HIV-Infected Patients in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22692090" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Second-line antiretroviral therapy: long-term outcomes in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22441252" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Lopinavir/ritonavir monotherapy after virologic failure of first-line antiretroviral therapy in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22427821" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Virologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16973982" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Undiagnosed tuberculosis in a community with high HIV prevalence: implications for tuberculosis control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20735240" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632522" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207078" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : High mortality among patients with AIDS who received a diagnosis of tuberculosis in the first 3 months of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20113978" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12086758" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17589190" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIV-infected patients in Rio de Janeiro, Brazil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17413692" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Prevalence, incidence and mortality associated with tuberculosis in HIV-infected patients initiating antiretroviral therapy in rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18520676" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Antiretroviral therapy for HIV-infected tuberculosis patients saves lives but needs to be used more frequently in Thailand.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18810685" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : HIV-associated tuberculosis: diagnostic and treatment challenges.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255740" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Tuberculosis-associated immune reconstitution disease: incidence, risk factors and impact in an antiretroviral treatment service in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20181971" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Timing of initiation of antiretroviral drugs during tuberculosis therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010913" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22010914" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Timing of antiretroviral therapy for HIV-1 infection and tuberculosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21596680" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Timing of initiation of antiretroviral therapy in human immunodeficiency virus (HIV)--associated tuberculous meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11740196" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : HIV, malaria parasites, and acute febrile episodes in Ugandan adults: a case-control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11009139" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effect of HIV-1 and increasing immunosuppression on malaria parasitaemia and clinical episodes in adults in rural Uganda: a cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11399962" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Increasing rates of malarial fever with deteriorating immune status in HIV-1-infected Ugandan adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16631881" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17504178" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Impact of antiretroviral therapy on the relapse of cryptococcosis and survival of HIV-infected patients with cryptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18769344" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : The use of HAART is associated with decreased risk of death during initial treatment of cryptococcal meningitis in adults in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20307571" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Outcomes of cryptococcal meningitis in antiretroviral naïve and experienced patients in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20334848" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15166532" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Impact of viral hepatitis co-infection on response to antiretroviral therapy and HIV disease progression in the HIV-NAT cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19772386" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18937580" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20470823" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18090386" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Antiretroviral drugs and liver injury.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10496904" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Role of Leishmania donovani and its lipophosphoglycan in CD4+ T-cell activation-induced human immunodeficiency virus replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419422" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Concordant HIV infection and visceral leishmaniasis in Ethiopia: the influence of antiretroviral treatment and other factors on outcome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6146009" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Acquired immunodeficiency syndrome in a heterosexual population in Zaire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2864575" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Slim disease: a new disease in Uganda and its association with HTLV-III infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20868276" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : The increasing burden of HIV-associated malignancies in resource-limited regions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16106415" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-Cancer Registry Match Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26267867" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Cancer Incidence following Expansion of HIV Treatment in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25844696" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A Population-Level Evaluation of the Effect of Antiretroviral Therapy on Cancer Incidence in Kyadondo County, Uganda, 1999-2008.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21767103" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Prevention of HIV-1 infection with early antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27658873" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27163694" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29509839" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Effect of Offering Same-Day ART vs Usual Health Facility Referral During Home-Based HIV Testing on Linkage to Care and Viral Suppression Among Adults With HIV in Lesotho: The CASCADE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29112073" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Benefits and risks of rapid initiation of antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10738050" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21091279" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784037" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784038" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23769234" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22784040" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Preexposure prophylaxis for HIV infection among African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539761" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Safety, adherence, and HIV-1 seroconversion among women using the dapivirine vaginal ring (DREAM): an open-label, extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33539762" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Safety, uptake, and use of a dapivirine vaginal ring for HIV-1 prevention in African women (HOPE): an open-label, extension study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27959766" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Safety and Efficacy of a Dapivirine Vaginal Ring for HIV Prevention in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26900902" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22110407" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474224" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : The cost-effectiveness of pre-exposure prophylaxis for HIV infection in South African women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31074936" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Dapivirine vaginal ring for HIV prevention: modelling health outcomes, drug resistance and cost-effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17620747" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Clinical impact and cost-effectiveness of antiretroviral therapy in India: starting criteria and second-line therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971720" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Cost-effectiveness of HIV treatment in resource-poor settings--the case of Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19620143" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : When to start antiretroviral therapy in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24171517" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Cost-effectiveness of HIV treatment as prevention in serodiscordant couples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18989232" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : CD4+ T-cell count monitoring does not accurately identify HIV-infected adults with virologic failure receiving antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18440426" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Outcomes from monitoring of patients on antiretroviral therapy in resource-limited settings with viral load, CD4 cell count, or clinical observation alone: a computer simulation model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26633768" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Sustainable HIV treatment in Africa through viral-load-informed differentiated care.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17879931" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Adverse effects of highly active antiretroviral therapy in developing countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20004464" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Routine versus clinically driven laboratory monitoring of HIV antiretroviral therapy in Africa (DART): a randomised non-inferiority trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20649436" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clinical impact and cost of monitoring for asymptomatic laboratory abnormalities among patients receiving antiretroviral therapy in a resource-poor setting.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18809819" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17545710" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : The cost effectiveness of antiretroviral treatment strategies in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17621241" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cost-effectiveness of alternative strategies for initiating and monitoring highly active antiretroviral therapy in the developing world.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20404739" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Laboratory monitoring to guide switching antiretroviral therapy in resource-limited settings: clinical benefits and cost-effectiveness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22074713" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : CD4 cell count and viral load monitoring in patients undergoing antiretroviral therapy in Uganda: cost effectiveness study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20482371" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Cost-effectiveness of laboratory monitoring in sub-Saharan Africa: a review of the current literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23087386" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : The clinical and economic impact of genotype testing at first-line antiretroviral therapy failure for HIV-infected patients in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232312" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d'Ivoire: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10232311" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15488218" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20495439" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Reducing mortality with cotrimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347483" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18784222" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20439953" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Plasmodium falciparum dihydrofolate reductase and dihyropteroate synthase mutations and the use of trimethoprim-sulfamethoxazole prophylaxis among persons infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21467024" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes? Results of a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28723333" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Enhanced Prophylaxis plus Antiretroviral Therapy for Advanced HIV Infection in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614918" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18614918" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Patterns of individual and population-level adherence to antiretroviral therapy and risk factors for poor adherence in the first year of the DART trial in Uganda and Zimbabwe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17768504" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : True outcomes for patients on antiretroviral therapy who are "lost to follow-up" in Malawi.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20397960" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Integrating HIV screening into routine health care in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516189" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Trends in CD4 count at presentation to care and treatment initiation in sub-Saharan Africa, 2002-2013: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28570507" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Trends in Prevalence of Advanced HIV Disease at Antiretroviral Therapy Enrollment - 10 Countries, 2004-2015.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26700300" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : CD4 count at antiretroviral therapy initiation and the risk of loss to follow-up: results from a multicentre cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16896111" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Adherence to antiretroviral therapy in sub-Saharan Africa and North America: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26679625" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Retention in Care and Patient-Reported Reasons for Undocumented Transfer or Stopping Care Among HIV-Infected Patients on Antiretroviral Therapy in Eastern Africa: Application of a Sampling-Based Approach.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983918" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15983918" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18466183" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Barriers to access to antiretroviral treatment in developing countries: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20442769" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Food insecurity as a barrier to sustained antiretroviral therapy adherence in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19504725" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Loss to care and death before antiretroviral therapy in Durban, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18373510" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Antiretroviral therapy in resource-limited settings 1996 to 2006: patient characteristics, treatment regimens and monitoring in sub-Saharan Africa, Asia and Latin America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18670668" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Early loss of HIV-infected patients on potent antiretroviral therapy programmes in lower-income countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19671185" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Mortality and loss-to-follow-up during the pre-treatment period in an antiretroviral therapy programme under normal health service conditions in Uganda.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20586956" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20380075" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941716" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17941716" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20586962" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Tracking a sample of patients lost to follow-up has a major impact on understanding determinants of survival in HIV-infected patients on antiretroviral therapy in Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19495419" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29889240" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Outcomes of Patients Lost to Follow-up in African Antiretroviral Therapy Programs: Individual Patient Data Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20003472" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Early severe morbidity and resource utilization in South African adults on antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17971708" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Characteristics and outcomes of adult patients lost to follow-up at an antiretroviral treatment clinic in johannesburg, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19859538" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Cost-effectiveness of preventing loss to follow-up in HIV treatment programs: a Côte d'Ivoire appraisal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25516092" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12799558" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Adherence is not a barrier to successful antiretroviral therapy in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31335865" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Adherence clubs and decentralized medication delivery to support patient retention and sustained viral suppression in care: Results from a cluster-randomized evaluation of differentiated ART delivery models in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20485480" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20485480" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Early adherence to antiretroviral medication as a predictor of long-term HIV virological suppression: five-year follow up of an observational cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30946148" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Minority and majority pretreatment HIV-1 drug resistance associated with failure of first-line nonnucleoside reverse-transcriptase inhibitor antiretroviral therapy in Kenyan women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22828485" id="rid168" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>169 : Global trends in antiretroviral resistance in treatment-naive individuals with HIV after rollout of antiretroviral treatment in resource-limited settings: a global collaborative study and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29198909" id="rid169" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>170 : HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30418575" id="rid170" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>171 : Prevalence of pretreatment HIV drug resistance in West African and Southeast Asian countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30597094" id="rid171" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>172 : HIV-1 drug resistance before initiation or re-initiation of first-line ART in eight regions of Mexico: a sub-nationally representative survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20185094" id="rid172" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>173 : Virological follow-up of adult patients in antiretroviral treatment programmes in sub-Saharan Africa: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578237" id="rid173" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>174 : HIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22474222" id="rid174" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>175 : Patterns of HIV-1 drug resistance after first-line antiretroviral therapy (ART) failure in 6 sub-Saharan African countries: implications for second-line ART strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20397305" id="rid175" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>176 : Outcomes after virologic failure of first-line ART in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19417582" id="rid176" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>177 : The public health approach to identify antiretroviral therapy failure: high-level nucleoside reverse transcriptase inhibitor resistance among Malawians failing first-line antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419495" id="rid177" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>178 : Prevalence of HIV-1 drug resistance after failure of a first highly active antiretroviral therapy regimen in KwaZulu Natal, South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24795328" id="rid178" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>179 : Drug susceptibility and resistance mutations after first-line failure in resource limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26831472" id="rid179" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>180 : Global epidemiology of drug resistance after failure of WHO recommended first-line regimens for adult HIV-1 infection: a multicentre retrospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476115" id="rid180" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>181 : Importance of routine viral load monitoring: higher levels of resistance at ART failure in Uganda and Lesotho compared with Switzerland.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23687289" id="rid181" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>182 : Emergence of HIV drug resistance during first- and second-line antiretroviral therapy in resource-limited settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19038438" id="rid182" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>183 : Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20617921" id="rid183" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>184 : Test and treat DC: forecasting the impact of a comprehensive HIV strategy in Washington DC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20154580" id="rid184" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>185 : Examining the promise of HIV elimination by 'test and treat' in hyperendemic settings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29199100" id="rid185" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>186 : Universal test and treat and the HIV epidemic in rural South Africa: a phase 4, open-label, community cluster randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314967" id="rid186" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>187 : Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314966" id="rid187" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>188 : HIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31314965" id="rid188" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>189 : Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639565" id="rid189" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>190 : Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639565" id="rid190" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>191 : Use of generic antiretroviral agents and cost savings in PEPFAR treatment programs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575155" id="rid191" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>192 : The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21575155" id="rid192" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>193 : The net cost of incorporating resistance testing into HIV/AIDS treatment in South Africa: a Markov model with primary data.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20639554" id="rid193" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>194 : One casualty of global economic crisis: uncertain finances for HIV/AIDS programs.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
